Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Vaccine
    September 2021
  1. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    >> Share

  2. YOSHIKAWA T
    Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01169.
    >> Share

  3. PARADOWSKA-STANKIEWICZ I, Rumik A, Bogusz J, Zbrzezniak J, et al
    Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
    Vaccine. 2021 Sep 9. pii: S0264-410X(21)01167.
    >> Share

  4. FUJISAWA S, Murata S, Takehara M, Aoyama J, et al
    In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01166.
    >> Share

  5. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    >> Share

  6. PLATT HL, Cardona JF, Haranaka M, Schwartz HI, et al
    A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01097.
    >> Share

  7. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    >> Share

  8. KUNITOKI K, Funato M, Mitsunami M, Kinoshita T, et al
    Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01145.
    >> Share

  9. MOLL K, Wong HL, Fingar K, Ke Zhou C, et al
    Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016-2018.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01151.
    >> Share

  10. VAN DONGEN JAP, Rouers EDM, Bonten MJM, Bruijning-Verhagen PCJ, et al
    Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01115.
    >> Share

  11. BHAT S, Caldera F, Farraye FA
    Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01121.
    >> Share

  12. RANE MS, Rohani P, Halloran ME
    Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01118.
    >> Share

  13. SISNOWSKI J, Vujovich-Dunn C, Gidding H, Brotherton J, et al
    Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01124.
    >> Share

  14. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01036.
    >> Share

  15. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01066.
    >> Share

  16. SONG JY, Chang CJ, Andrews C, Diez-Domingo J, et al
    Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged>/=50years: A randomized phase III trial (PNEU-PATH).
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01071.
    >> Share

  17. LAWRENCE J, Kitchin N, Anderson AS, Pride MW, et al
    Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)00592.
    >> Share

  18. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    >> Share

  19. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01112.
    >> Share

  20. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    The role of maturity in adolescent decision-making around HPV vaccination in France.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01156.
    >> Share

  21. ALI A, Dwyer D, Wu Q, Wang Q, et al
    Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01126.
    >> Share

  22. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    >> Share

  23. ZAMAN K, Kovacs SD, Vanderende K, Aziz A, et al
    Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01113.
    >> Share

  24. BARRY M, Temsah MH, Aljamaan F, Saddik B, et al
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01131.
    >> Share

  25. KOTLER L, Greenberg D, Givon-Lavi N, van der Beek BA, et al
    Decline in pneumococcal nasopharyngeal carriage in children 6-23 months with respiratory illnesses following pneumococcal conjugate vaccine implementation.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01130.
    >> Share

  26. CLAYTON K, Finley C, Flynn DJ, Graves M, et al
    Evaluating the effects of vaccine messaging on immunization intentions and behavior: Evidence from two randomized controlled trials in Vermont.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01095.
    >> Share

  27. AZAM JM, Saitta B, Bonner K, Ferrari MJ, et al
    Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01101.
    >> Share

    August 2021
  28. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    >> Share

  29. TROGSTAD L, Robertson AH, Mjaaland S, Magnus P, et al
    Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01103.
    >> Share

  30. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    >> Share

  31. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    >> Share

  32. FOWLER A, Sampson M, Remaley AT, Chackerian B, et al
    A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01125.
    >> Share

  33. BROSH-NISSIMOV T, Sorek N, Yeshayahu M, Zherebovich I, et al
    Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01148.
    >> Share

  34. BATOOL R, Tahir Yousafzai M, Qureshi S, Ali M, et al
    Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01099.
    >> Share

  35. CAMPBELL JD, Pasetti MF, Oot L, Adam Z, et al
    Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01119.
    >> Share

  36. BAQUI AH, Koffi AK, McCollum ED, Roy AD, et al
    Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies.
    Vaccine. 2021 Aug 28. pii: S0264-410X(21)01116.
    >> Share

  37. PRELOG M, Almanzar G, Stern R, Robrade K, et al
    Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)01049.
    >> Share

  38. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    >> Share

  39. MALTEZOU HC, Effraimidou E, Cassimos DC, Medic S, et al
    Vaccination programs for pregnant women in Europe, 2021.
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)01122.
    >> Share

  40. GORANDER S, Honda-Okubo Y, Backstrom M, Baldwin J, et al
    A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01098.
    >> Share

  41. SILCOCK R, Moghimi A, Perrett K, Crawford N, et al
    Subcutaneous nodule at the vaccine injection site - A case of mistaken identity.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01069.
    >> Share

  42. NOWAK SA, Gidengil CA, Parker AM, Matthews LJ, et al
    Association among trust in health care providers, friends, and family, and vaccine hesitancy.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01068.
    >> Share

  43. HARPAZ R
    COVID-19 vaccine safety monitoring: Might differential healthcare seeking introduce detection bias into rates of medical events and cause false safety signals?
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)00712.
    >> Share

  44. AZIZ AB, Zaman K, Kim DR, Park JY, et al
    Re-evaluation of population-level protection conferred by a rotavirus vaccine using the 'fried-egg' approach in a rural setting in Bangladesh.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01096.
    >> Share

  45. DECKER MD, Garman PM, Hughes H, Yacovone MA, et al
    Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01074.
    >> Share

  46. KUROKAWA N, Robinson MK, Bernard C, Kawaguchi Y, et al
    Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01100.
    >> Share

  47. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share

  48. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    >> Share

  49. ODUWOLE EO, Mahomed H, Laurenzi CA, Larson HJ, et al
    Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01102.
    >> Share

  50. ROTENBERG S, Downer MB, Cooper J
    Making COVID-19 vaccinations accessible for people with disabilities.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01110.
    >> Share

  51. MORAIS E, El Mouaddin N, Schuurman S, De A, et al
    Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01076.
    >> Share

  52. MORIKAWA Y, Sakakibara H, Kimiya T, Obonai T, et al
    Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01011.
    >> Share

  53. SUZUKI H, Noguchi T, Ogawa K, Miyazato P, et al
    Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae.
    Vaccine. 2021;39:5146-5152.
    >> Share

  54. AHMED D, VanderEnde K, Harvey P, Bhatnagar P, et al
    Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019.
    Vaccine. 2021 Aug 21. pii: S0264-410X(21)00901.
    >> Share

  55. HAUSI H, Nicks P, Mzengeza T, Tsega A, et al
    The challenge of identifying eligible girls for HPV vaccination: HPV mapping data verification in Malawi.
    Vaccine. 2021 Aug 20. pii: S0264-410X(21)00902.
    >> Share

  56. NIKOLAY B, Ribeiro Dos Santos G, Lipsitch M, Rahman M, et al
    Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh.
    Vaccine. 2021 Aug 20. pii: S0264-410X(21)01047.
    >> Share

  57. DUDLEY MZ, Bernier R, Brewer J, Salmon DA, et al
    Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01070.
    >> Share

  58. JUNG Y, Min JY, Kim HJ, Min KB, et al
    Disparities in infant mortality from all-infectious, vaccine-preventable, and non-vaccine preventable diseases in relation to parental education.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01012.
    >> Share

  59. VENEGAS-VARGAS C, Taylor LP, Foss DL, Godbee TK, et al
    Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01033.
    >> Share

  60. ZHANG N, Zheng T, Chen Y, Zhu H, et al
    Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01007.
    >> Share

  61. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    >> Share

  62. BRAEYE T, Cornelissen L, Catteau L, Haarhuis F, et al
    Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01108.
    >> Share

  63. LEE T, Gutierrez RL, Maciel M, Poole S, et al
    Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01065.
    >> Share

  64. HUANG XX, Bose AS, Gupta BP, Rai P, et al
    Vaccine preventable diseases surveillance in Nepal: How much does it cost?
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)00915.
    >> Share

  65. KARAFILLAKIS E, Paterson P, Larson HJ
    'My primary purpose is to protect the unborn child': Understanding pregnant women's perceptions of maternal vaccination and vaccine trials in Europe.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01014.
    >> Share

  66. BEDFORD H, Firman N, Waller J, Marlow L, et al
    Which young women are not being vaccinated against HPV? Cross-sectional analysis of a UK national cohort study.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01005.
    >> Share

  67. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01037.
    >> Share

  68. NACIUTE M, Kiwitt T, Kemp RA, Hook S, et al
    Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration.
    Vaccine. 2021 Aug 18. pii: S0264-410X(21)01048.
    >> Share

  69. LIU S, Liu J
    Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01106.
    >> Share

  70. MVUNDURA M, Frivold C, Janik Osborne A, Soni P, et al
    Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01044.
    >> Share

  71. JIANG Y, Li X, Yu L, Tong W, et al
    Immune efficacy of a candidate porcine reproductive and respiratory syndrome vaccine rHN-NP49 administered by a Needle-free intradermal delivery system in comparison with intramuscular injection.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01043.
    >> Share

  72. HASSAN AS, Perera DJ, Ward BJ, Ndao M, et al
    Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01051.
    >> Share

  73. LAIGLE V, Postma MJ, Pavlovic M, Cadeddu C, et al
    Vaccine market access pathways in the EU27 and the United Kingdom-analysis and recommendations for improvements.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)00918.
    >> Share

  74. JANSSEN RS, Bruxvoort K, Jacobsen SJ, Slezak J, et al
    Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01015.
    >> Share

  75. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    >> Share

  76. PRESTON KB, Wong TAS, To A, Tashiro TE, et al
    Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01002.
    >> Share

  77. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01035.
    >> Share

  78. RODRIGUES DE OLIVEIRA N, Jorge S, Andrade Colares Maia M, Thurow Bunde T, et al
    Protective efficacy of whole-cell inactivated Leptospira vaccines made using virulent or avirulent strains in a hamster model.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01034.
    >> Share

  79. CIAPPONI A, Bardach A, Mazzoni A, Alconada T, et al
    Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01067.
    >> Share

  80. SCHLEISS MR, John CC, Permar SR
    Children are the key to the Endgame: A case for routine pediatric COVID vaccination.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01004.
    >> Share

  81. ROBERTSON RC, Church JA, Edens TJ, Mutasa K, et al
    The fecal microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)00981.
    >> Share

  82. WEBSTER H, Valencia S, Kumar A, Chan C, et al
    Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01029.
    >> Share

  83. IWAMOTO M, Hickman CJ, Colley H, Arciuolo RJ, et al
    Measles infection in persons with secondary vaccine failure, New York City, 2018-19.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)00983.
    >> Share

  84. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    >> Share

  85. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    >> Share

  86. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    >> Share

  87. OKAMURA S, Ebina H
    Could live attenuated vaccines better control COVID-19?
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01038.
    >> Share

  88. KANJI JN, Bailey A, Fenton J, Ling SH, et al
    Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01042.
    >> Share

  89. RIZK JG, Barr CE, Rizk Y, Lewin JC, et al
    The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action.
    Vaccine. 2021 Aug 10. pii: S0264-410X(21)01006.
    >> Share

  90. GALOR I, Hartal M, Perry Markovich M, Avramovich E, et al
    Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule: Response letter, to letter to the editor.
    Vaccine. 2021;39:4777.
    >> Share

  91. HERZOG C
    Immune memory persistence is well documented for hepatitis A vaccines.
    Vaccine. 2021;39:4775-4776.
    >> Share

  92. STAPLES JN, Nelamangala SL, Morris S, Wells K, et al
    Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00984.
    >> Share

  93. GOUD R, Thompson D, Welsh K, Lu M, et al
    ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)01003.
    >> Share

  94. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    >> Share

  95. KRISTINSDOTTIR I, Haraldsson A, Love A, Asgeirsdottir TL, et al
    Burden of rotavirus disease in young children in Iceland - Time to vaccinate?
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00944.
    >> Share

  96. BRITTON KJ, Pickering JL, Pomat WS, de Gier C, et al
    Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00990.
    >> Share

  97. ILLOUZ T, Madar R, Hirsh T, Biragyn A, et al
    Induction of an effective anti-Amyloid-beta humoral response in aged mice.
    Vaccine. 2021;39:4817-4829.
    >> Share

  98. PHILLIPS A, Carlson S, Danchin M, Beard F, et al
    From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00950.
    >> Share

  99. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    >> Share

  100. YLADE M, Agrupis KA, Daag JV, Crisostomo MV, et al
    Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00920.
    >> Share

  101. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    >> Share

  102. ELDRIDGE JH, Egan MA, Matassov D, Hamm S, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00907.
    >> Share

  103. BORGHI L, Riva E
    Was Aldo Castellani the inventor of combined and polyvalent vaccines?
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00955.
    >> Share

  104. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    >> Share

  105. MILLER CN, Kemp TJ, Abrahamsen M, Isaacs-Soriano K, et al
    Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00962.
    >> Share

  106. TAYLOR SC, Hurst B, Martiszus I, Hausman MS, et al
    Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)01013.
    >> Share

  107. JOHM P, Nkoum N, Ceesay A, Mbaye EH, et al
    Erratum to 'Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal' [Vaccine 39 (2021) 3926-3934].
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00991.
    >> Share

  108. WILSON R
    HPV vaccine acceptance in West Africa: A systematic literature review.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00835.
    >> Share

  109. CHHATWAL J, Sapru A, Sundaram B, Shenoy B, et al
    A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00946.
    >> Share

  110. DODD RH, Pickles K, Cvejic E, Cornell S, et al
    Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01008.
    >> Share

  111. HVASS AMF, Norredam M, Sodemann M, Thomsen MK, et al
    Corrigendum to 'Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study' [Vaccine 38 (2020) 2788-2794].
    Vaccine. 2021 Aug 4. pii: S0264-410X(21)00993.
    >> Share

  112. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    >> Share

  113. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    >> Share

  114. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    >> Share

  115. SUN J, Zheng Z, Li M, Liu Z, et al
    Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+ T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice.
    Vaccine. 2021 Aug 2. pii: S0264-410X(21)00913.
    >> Share

  116. LEIDNER AJ, Tang Z, Guo A, Anderson TC, et al
    Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Vaccine. 2021 Aug 2. pii: S0264-410X(21)00928.
    >> Share

    July 2021
  117. LITWIN C, Smith L, Donken R, Krajden M, et al
    High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00868.
    >> Share

  118. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Corrigendum to "Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations" [Vaccine 38(51) (2020) 8206-8215].
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00963.
    >> Share

  119. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    >> Share

  120. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    >> Share

  121. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    >> Share

  122. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    >> Share

  123. LUCINDE RK, Ong'ayo G, Houlihan C, Bottomley C, et al
    Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00910.
    >> Share

  124. JONES A, Kawesa-Newell N
    Using branded behaviour change communication to create demand for the HPV vaccine among girls in Malawi: An evaluation of Girl Effect's Zathu mini magazine.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00870.
    >> Share

  125. DOI H, Kanto T
    Factors influencing the durability of hepatitis B vaccine responses.
    Vaccine. 2021 Jul 30. pii: S0264-410X(21)00876.
    >> Share

  126. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    >> Share

  127. VELANDIA-GONZALEZ M, Vilajeliu A, Contreras M, Trumbo SP, et al
    Monitoring progress of maternal and neonatal immunization in Latin America and the Caribbean.
    Vaccine. 2021;39 Suppl 2:B55-B63.
    >> Share

  128. KOBAYASHI M, Abdul-Karim A, Milucky JL, Zakariah A, et al
    Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction.
    Vaccine. 2021;39:4685-4699.
    >> Share

  129. LIM H, In HJ, Kim YJ, Jang S, et al
    Development of an attenuated smallpox vaccine candidate: The KVAC103 strain.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00810.
    >> Share

  130. CARRICO J, Talbird SE, La EM, Poston S, et al
    Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00906.
    >> Share

  131. DALON F, Majed L, Belhassen M, Jacoud F, et al
    Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study.
    Vaccine. 2021 Jul 29. pii: S0264-410X(21)00945.
    >> Share

  132. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    >> Share

  133. GARLASCO J, Bordino V, Marengo N, Rainero E, et al
    Pertussis immunisation during pregnancy: Antibody levels and the impact of booster vaccine.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00930.
    >> Share

  134. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    >> Share

  135. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    >> Share

  136. VINK M, Upadhaya N, Amin HA, Liwal MG, et al
    Does support to Private Health Practitioners increase childhood vaccination coverage? Findings from a comparative study in Afghanistan.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00877.
    >> Share

  137. KHAN SA, Choudhury P, Kakati S, Doley R, et al
    Effectiveness of a single dose of Japanese encephalitis vaccine among adults, Assam, India, 2012-2018.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00919.
    >> Share

  138. KUROKAWA N, Lavoie PO, D'Aoust MA, Couture MM, et al
    Development and characterization of a plant-derived rotavirus-like particle vaccine.
    Vaccine. 2021 Jul 26. pii: S0264-410X(21)00916.
    >> Share

  139. KLEIN NP, Peyrani P, Yacisin K, Caldwell N, et al
    A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00863.
    >> Share

  140. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    >> Share

  141. MICHOS A, Tatsi EB, Filippatos F, Dellis C, et al
    Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00960.
    >> Share

  142. ALVES MLF, Ferreira MRA, Donassolo RA, Rodrigues RR, et al
    Clostridium septicum: A review in the light of alpha-toxin and development of vaccines.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00878.
    >> Share

  143. BURKE PF, Masters D, Massey G
    Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00947.
    >> Share

  144. TEASDALE CA, Borrell LN, Shen Y, Kimball S, et al
    Parental plans to vaccinate children for COVID-19 in New York city.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00949.
    >> Share

  145. SUNDARAM M, Nasreen S, Calzavara A, He S, et al
    Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00951.
    >> Share

  146. CALLAHAN AG, Coleman-Cowger VH, Schulkin J, Power ML, et al
    Racial disparities in influenza immunization during pregnancy in the United States: A narrative review of the evidence for disparities and potential interventions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00905.
    >> Share

  147. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    >> Share

  148. TISSOT N, Brunel AS, Bozon F, Rosolen B, et al
    Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00925.
    >> Share

  149. MATHIVATHANAN K
    Will COVID-19 vaccine equity be possible in India?
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00927.
    >> Share

  150. HERVE PL, Dhelft V, Zuniga A, Ghasparian A, et al
    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Vaccine. 2021;39:4555-4563.
    >> Share

  151. VODICKA E, Nonvignon J, Antwi-Agyei KO, Bawa J, et al
    The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.
    Vaccine. 2021 Jul 21. pii: S0264-410X(21)00904.
    >> Share

  152. JACKSON B, Harvey Y, Perez-Martin E, Wilsden G, et al
    The selection of naturally stable candidate foot-and-mouth disease virus vaccine strains for East Africa.
    Vaccine. 2021 Jul 21. pii: S0264-410X(21)00860.
    >> Share

  153. PAUL E, Brown GW, Kalk A, Ridde V, et al
    Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00923.
    >> Share

  154. CHUA H, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00873.
    >> Share

  155. HECHT J, Suliman S, Wegiel B
    Bacillus Calmette-Guerin (BCG) vaccination to treat endometriosis.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00879.
    >> Share

  156. INGROLE RSJ, Tao W, Joshi G, Gill HS, et al
    M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00909.
    >> Share

  157. CORCORAN M, Mereckiene J, Cotter S, Murchan S, et al
    Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00741.
    >> Share

  158. COLTON H, Greenfield DM, Snowden JA, Miller PDE, et al
    Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant.
    Vaccine. 2021 Jul 19. pii: S0264-410X(21)00881.
    >> Share

  159. MADHIVANAN P, Krupp K, Coudray M, Colbert B, et al
    Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities.
    Vaccine. 2021 Jul 19. pii: S0264-410X(21)00903.
    >> Share

  160. HANLY M, Churches T, Fitzgerald O, MacIntyre CR, et al
    Vaccinating Australia: How long will it take?
    Vaccine. 2021 Jul 17. pii: S0264-410X(21)00865.
    >> Share

  161. SHILLING H, Garland SM, Atchison S, Cornall AM, et al
    Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00864.
    >> Share

  162. FLUCKIGER AC, Ontsouka B, Bozic J, Diress A, et al
    An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00911.
    >> Share

  163. INSERRA F, Tajer C, Antonietti L, Mariani J, et al
    Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00908.
    >> Share

  164. PATHIRANA J, Kwatra G, Maposa I, Groome MJ, et al
    Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00661.
    >> Share

  165. LAMONTAGNE DS, Manangazira P, Marembo J, Chigodo C, et al
    HPV vaccination coverage in three districts in ZIMBABWE following national introduction of 0,12 month schedule among 10 to 14 year old girls.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00871.
    >> Share

  166. ELAS M, Villatoro N, Pezzoli L
    Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00869.
    >> Share

  167. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    >> Share

  168. O'DELL FJ, Williams AN, Poland A
    The contributions of William Money MRCS to smallpox vaccination and control - A little-known story.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00844.
    >> Share

  169. HAYMAN B, Suri R, Prasad SD
    COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00866.
    >> Share

  170. LAZAROS G, Klein AL, Hatziantoniou S, Tsioufis C, et al
    The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00875.
    >> Share

  171. WANG X, Xia A, Wang C, Tian H, et al
    Clinical and molecular characterization of the first culture-confirmed pediatric fulminant meningococcemia case caused by a serogroup Y clonal complex 23 strain in China.
    Vaccine. 2021;39:4261-4265.
    >> Share

  172. TONG L, Jia Q, Li B, Li Z, et al
    Investigation of the baseline tetanus antibody level and its persistence in a military unit.
    Vaccine. 2021;39:4328-4334.
    >> Share

  173. CLARKE M, Goodchild LM, Evans S, Giles LC, et al
    Body mass index and vaccine responses following influenza vaccination during pregnancy.
    Vaccine. 2021 Jul 12. pii: S0264-410X(21)00826.
    >> Share

  174. GOMEZ M, McCollum J, Wang H, Bachchhav S, et al
    Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00861.
    >> Share

  175. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    >> Share

  176. GUKTUR RE, Nep EI, Asala O, Olorunfemi PO, et al
    Carboxymethylated and acetylated xerogel derivatives of Plectranthus esculentus starch protect Newcastle disease vaccines against cold chain failure.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00812.
    >> Share

  177. ZHANG T, Zhang J, Shao X, Feng S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00836.
    >> Share

  178. FONGWEN N, Delrieu I, Ham LH, Gubler DJ, et al
    Implementation strategies for the first licensed dengue vaccine: A meeting report.
    Vaccine. 2021 Jul 9. pii: S0264-410X(21)00845.
    >> Share

  179. TERNA RICHARD M, Taiwo L, Jean Baptiste AE, Bawa S, et al
    Planning for supplemental immunization activities using the readiness assessment dashboard: Experience from 2017/2018 Measles vaccination campaign, Nigeria.
    Vaccine. 2021 Jul 8. pii: S0264-410X(21)00831.
    >> Share

  180. MATEO-URDIALES A, Del Manso M, Andrianou X, Spuri M, et al
    Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00862.
    >> Share

  181. DING Y, Luo L, Luo Y, Zhao D, et al
    A novel combined vaccine against classical swine fever and porcine epidemic diarrhea viruses elicits a significant Th2-favored humoral response in mice.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00846.
    >> Share

  182. AT THOBARI J, Damayanti W, Haposan JH, Nirwati H, et al
    Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
    Vaccine. 2021 Jul 6. pii: S0264-410X(21)00832.
    >> Share

  183. GESSNER BD, Theilacker C, Mendez C, Jodar L, et al
    Comment on "Vila-Corcoles et al., Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016."
    Vaccine. 2021;39:4032-4033.
    >> Share

  184. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    >> Share

  185. OZAWA S, Yemeke TT, Mitgang E, Wedlock PT, et al
    Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00581.
    >> Share

  186. GENTILE A, Pacchiotti AC, Giglio N, Nolte MF, et al
    Vaccine hesitancy in Argentina: Validation of WHO scale for parents.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00842.
    >> Share

  187. MARTIN C, Marinova D, Aguilo N, Gonzalo-Asensio J, et al
    MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG.
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00799.
    >> Share

  188. GOSSET A, Diallo MY, Betsem E, Schaeffer L, et al
    Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study).
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00809.
    >> Share

  189. KURITA J, Uematsu T, Sakurai N, Sugawara T, et al
    Attenuation of antibody titer of measles and rubella virus among university students of department of healthcare providers during 2015-2018 in Japan.
    Vaccine. 2021;39:4203-4209.
    >> Share

  190. LUO J, Huo C, Qin H, Hu J, et al
    Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection.
    Vaccine. 2021;39:4135-4143.
    >> Share

  191. SIMAS C, Paterson P, Lees S, J Larson H, et al
    "From my phone, I could rule the world": Critical engagement with maternal vaccine information, vaccine confidence builders and post-Zika outbreak rumours in Brazil.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00775.
    >> Share

  192. LI AJ, Manzi F, Kyesi F, Makame Y, et al
    Tanzania's human papillomavirus (HPV) vaccination program: Community awareness, feasibility, and acceptability of a national HPV vaccination program, 2019.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00797.
    >> Share

  193. HUANG Y, Seaton KE, Casapia M, Polakowski L, et al
    AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00827.
    >> Share

  194. SCHALTZ-BUCHHOLZER F, Roth A, de Bree LCJ, Biering-Sorensen S, et al
    Neonatal Bacille Calmette-Guerin vaccination and tuberculin skin test reactions at 2- and 6-months: Effects on mortality up to 1 year of age.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00839.
    >> Share

  195. LO CY, Misplon JA, Li X, Price GE, et al
    Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00833.
    >> Share

  196. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    >> Share

  197. THIEM VD, Anh DD, Ha VH, Hien ND, et al
    Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00806.
    >> Share

  198. CHOWDHURY F, Ali Syed K, Akter A, Rahman Bhuiyan T, et al
    A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol(R), an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00830.
    >> Share

  199. YEMEKE TT, Mitgang E, Wedlock PT, Higgins C, et al
    Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers.
    Vaccine. 2021 Jul 1. pii: S0264-410X(21)00670.
    >> Share

    June 2021
  200. MWABA J, Chisenga CC, Xiao S, Ng'ombe H, et al
    Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00770.
    >> Share

  201. SORENSEN MK, Schaltz-Buchholzer F, Jensen AM, Nielsen S, et al
    Retesting the hypothesis that early Diphtheria-Tetanus-Pertussis vaccination increases female mortality: An observational study within a randomised trial.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00720.
    >> Share

  202. HINES AM, Murphy N, Mullin C, Barillas J, et al
    Henoch-Schonlein purpura presenting post COVID-19 vaccination.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00841.
    >> Share

  203. FISCHER P, Pawlowski A, Cao D, Bell D, et al
    Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00796.
    >> Share

  204. OSTERGAARD L, Vesikari T, Senders SD, Flodmark CE, et al
    Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00717.
    >> Share

  205. PLUTZER E, Warner SB
    A potential new front in health communication to encourage vaccination: Health education teachers.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00800.
    >> Share

  206. KAUR R, Pham M, Pichichero M
    Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.
    Vaccine. 2021;39:3900-3906.
    >> Share

  207. KELLY SM, Larsen KR, Darling R, Petersen AC, et al
    Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.
    Vaccine. 2021;39:3862-3870.
    >> Share

  208. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    >> Share

  209. BANKS C, Portnoy A, Moi F, Boonstoppel L, et al
    Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00838.
    >> Share

  210. VERGER P, Duale C, Lenzi N, Scronias D, et al
    Vaccine hesitancy among hospital staff physicians: A cross-sectional survey in France in 2019.
    Vaccine. 2021 Jun 28. pii: S0264-410X(21)00803.
    >> Share

  211. BURNETT E, Juin S, Esona MD, Desormeaux AM, et al
    Effectiveness of monovalent rotavirus vaccine against hospitalizations due to all rotavirus and equine-like G3P[8] genotypes in Haiti 2014-2019.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00805.
    >> Share

  212. SARHAN AT, Bahey-El-Din M, Zaghloul TI
    Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00801.
    >> Share

  213. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    >> Share

  214. FELIX S, Handem S, Nunes S, Paulo AC, et al
    Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00771.
    >> Share

  215. CARNALLA M, Torres-Ibarra L, Barrientos-Gutierrez T, Cruz-Valdez A, et al
    Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00776.
    >> Share

  216. MYLES IA, Vinciguerra JS, Premus RT
    Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00811.
    >> Share

  217. TUO W, Feng X, Cao L, Vinyard B, et al
    Vaccination with Neospora caninum-cyclophilin and -profilin confers partial protection against experimental neosporosis-induced abortion in sheep.
    Vaccine. 2021 Jun 24. pii: S0264-410X(21)00768.
    >> Share

  218. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    >> Share

  219. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    >> Share

  220. FURUYA-KANAMORI L, Xu C, Doi SAR, Clark J, et al
    Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00759.
    >> Share

  221. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    >> Share

  222. MARTIN-MERINO E, Castillo-Cano B, Martin-Perez M, Llorente-Garcia A, et al
    Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00765.
    >> Share

  223. KRISTENSEN D, Giersing B, Hickling J, Kazi F, et al
    A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00711.
    >> Share

  224. PHILLIP K, Nair N, Samanta K, Azevedo JF, et al
    Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00761.
    >> Share

  225. OOSTDIJK C, Van Zoonen K, Ruijs WLM, Mollema L, et al
    Household decision-making for the MenACWY vaccination: How parents and adolescents deal with an adolescent vaccination decision.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00772.
    >> Share

  226. TRENT M, Seale H, Chughtai AA, Salmon D, et al
    Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00798.
    >> Share

  227. JAYARAMAN Y, Veeraraghavan B, Girish Kumar CP, Sukumar B, et al
    Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India.
    Vaccine. 2021;39:3737-3744.
    >> Share

  228. MBAEYI C, Moran T, Wadood Z, Ather F, et al
    Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Vaccine. 2021;39:3717-3723.
    >> Share

  229. GOOCH KE, Smith TRF, Salguero FJ, Fotheringham SA, et al
    One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00807.
    >> Share

  230. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    >> Share

  231. CHEN IH, Ahorsu DK, Ko NY, Yen CF, et al
    Adapting the Motors of Influenza Vaccination Acceptance Scale into the Motors of COVID-19 Vaccination Acceptance Scale: Psychometric evaluation among mainland Chinese university students.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00794.
    >> Share

  232. WANG Z, Zhou C, Gao F, Zhu Q, et al
    Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): Immunogenicity, efficacy and toxicology.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00767.
    >> Share

  233. RADHAKRISHNAN L, Stein Z, DeVies J, Smith A, et al
    Syndromic surveillance of vaccine-associated adverse events in U.S. emergency departments.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00766.
    >> Share

  234. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    >> Share

  235. WEDLOCK PT, Cox SN, Bartsch SM, Randall SL, et al
    Should countries switch to using five- or ten-dose rotavirus vaccines now that they are available?
    Vaccine. 2021 Jun 19. pii: S0264-410X(21)00757.
    >> Share

  236. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    >> Share

  237. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    >> Share

  238. LILES E, Irving SA, Dandamudi P, Belongia EA, et al
    Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination.
    Vaccine. 2021;39:3614-3620.
    >> Share

  239. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    >> Share

  240. VAILLANT L, Oster P, McMillan B, Velin D, et al
    Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy.
    Vaccine. 2021;39:3590-3601.
    >> Share

  241. JETHWA H, Wong R, Abraham S
    Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
    Vaccine. 2021;39:3541-3543.
    >> Share

  242. PRASAD N, Read JM, Jewell C, Waite B, et al
    Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00708.
    >> Share

  243. FRADICO JRB, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JGA, et al
    CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00709.
    >> Share

  244. YITBAREK K, Tilahun T, Debela T, Abdena D, et al
    Measles epidemiology and vaccination coverage in Oromia Region, Ethiopia: Evidence from surveillance, 2011-2018.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00739.
    >> Share

  245. MOSS WJ, Shendale S, Lindstrand A, O'Brien KL, et al
    Feasibility assessment of measles and rubella eradication.
    Vaccine. 2021;39:3544-3559.
    >> Share

  246. ANDRE GO, Borges MT, Assoni L, Ferraz LFC, et al
    Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis.
    Vaccine. 2021;39:3626-3632.
    >> Share

  247. GARON JR, Mukavhi A, Rupfutse M, Bright S, et al
    Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00669.
    >> Share

  248. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    >> Share

  249. SMITH LE, Hodson A, Rubin GJ
    Parental attitudes towards mandatory vaccination; a systematic review.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00742.
    >> Share

  250. IVANOV V, Oomens AGP, Papin JF, Staats R, et al
    Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00737.
    >> Share

  251. KOCHHAR GS, Desai A, Caldera DO F, El Hachem S, et al
    Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00615.
    >> Share

  252. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    >> Share

  253. SCHALTZ-BUCHHOLZER F, Kjaer Sorensen M, Benn CS, Aaby P, et al
    The introduction of BCG vaccination to neonates in Northern Sweden, 1927-31: Re-analysis of historical data to understand the lower mortality among BCG-vaccinated children.
    Vaccine. 2021 Jun 13. pii: S0264-410X(21)00718.
    >> Share

  254. LIPSITCH M, Kahn R
    Interpreting vaccine efficacy trial results for infection and transmission.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00735.
    >> Share

  255. FERRARI D, Di Resta C, Tomaiuolo R, Sabetta E, et al
    Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00756.
    >> Share

  256. MCFADDEN K, Heywood A, Dyda A, Kaufman J, et al
    Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
    Vaccine. 2021;39:3467-3472.
    >> Share

  257. DAVIES C, Stoney T, Hutton H, Parrella A, et al
    School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00637.
    >> Share

  258. BEAU RENEER Z, Abreu RB, Jamal US, Corn MR, et al
    Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00659.
    >> Share

  259. MESHER D, Thomas SL, Linley E, Edmundson C, et al
    Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00580.
    >> Share

  260. OH SH, Kim SH, Jeon JH, Kim EB, et al
    Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00734.
    >> Share

  261. HSIA J, Zhao G, Lu PJ, Town M, et al
    Estimating bias from internet non-use for a hybrid web vaccination survey - 2013-2017 Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00675.
    >> Share

  262. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    >> Share

  263. CHEN Y, Wang Y, Robertson ID, Hu C, et al
    Key issues affecting the current status of infectious diseases in Chinese cattle farms and their control through vaccination.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00673.
    >> Share

  264. RAHMAN T, de Gier C, Orami T, Seppanen EJ, et al
    PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life.
    Vaccine. 2021;39:3486-3492.
    >> Share

  265. SORG AL, Obermeier V, Liese JG, von Kries R, et al
    Incidence trends of parapneumonic pleural effusions/empyema in children 2009 to 2018 from health insurance data: Only temporal reduction after the introduction of PCV13.
    Vaccine. 2021;39:3516-3519.
    >> Share

  266. CHAUHAN AS, Kapoor I, Rana SK, Kumar D, et al
    Cost effectiveness of typhoid vaccination in India.
    Vaccine. 2021 Jun 10. pii: S0264-410X(21)00713.
    >> Share

  267. VANDERSLOTT S, Marks T
    Charting mandatory childhood vaccination policies worldwide.
    Vaccine. 2021 Jun 10. pii: S0264-410X(21)00547.
    >> Share

  268. LUTZ CS, Biggerstaff M, Rolfes MA, Lafond KE, et al
    Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00557.
    >> Share

  269. MUHI S, Stinear TP
    Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00700.
    >> Share

  270. GUNTUKU SC, Buttenheim AM, Sherman G, Merchant RM, et al
    Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00738.
    >> Share

  271. HOEHL S, Ciesek S, Graf J, Wicker S, et al
    A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00736.
    >> Share

  272. DE VRIES LM, Kellerborg KM, Brouwer WBF, van Baal PHM, et al
    Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00699.
    >> Share

  273. STOECKEL F, Carter C, Lyons BA, Reifler J, et al
    Association of vaccine hesitancy and immunization coverage rates in the European Union.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00657.
    >> Share

  274. SUN Y, Jackson K, Dalmon CA, Shapiro BL, et al
    Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00642.
    >> Share

  275. DIAZ-MITOMA F, Popovic V, Spaans JN
    Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: A phase 3 randomized clinical trial.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00662.
    >> Share

  276. ANDAYI F, Emukule GO, Osoro E, Ndegwa LK, et al
    Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemic.
    Vaccine. 2021 Jun 7. pii: S0264-410X(21)00643.
    >> Share

  277. RAZ A, Keshet Y, Popper-Giveon A, Karkabi MS, et al
    One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.
    Vaccine. 2021 Jun 5. pii: S0264-410X(21)00714.
    >> Share

  278. CHUA JV, Davis C, Husson JS, Nelson A, et al
    Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00685.
    >> Share

  279. NOGUERA M, Vela A, Kraft C, Chevalier M, et al
    Effects of three commercial vaccines against porcine parvovirus 1 in pregnant gilts.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00614.
    >> Share

  280. KARAFILLAKIS E, Francis MR, Paterson P, Larson HJ, et al
    Trust, emotions and risks: Pregnant women's perceptions, confidence and decision-making practices around maternal vaccination in France.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00704.
    >> Share

  281. WOLFE LS, Smedley JG 3rd, Bubna N, Hussain A, et al
    Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00668.
    >> Share

  282. DAL-RE R, Launay O
    Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00703.
    >> Share

  283. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    >> Share

  284. CHANDRA D, Vipin B
    On the vaccine supply chain coordination under subsidy contract.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00676.
    >> Share

  285. STUURMAN AL, Biccler J, Carmona A, Descamps A, et al
    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00654.
    >> Share

  286. UWINS C, Cyriac S, Bhandoria G
    HPV vaccine: Expanding indications and global disparity.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00677.
    >> Share

  287. GATES A, Rahman S, Sim S, Pillay J, et al
    Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00640.
    >> Share

  288. FERDINANDS JM, Thompson MG, Blanton L, Spencer S, et al
    Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00562.
    >> Share

  289. LASKY T, McMahon AW, Hua W, Forshee R, et al
    Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00666.
    >> Share

  290. SHINGAI M, Nomura N, Sekiya T, Ohno M, et al
    Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00660.
    >> Share

  291. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    >> Share

  292. JOHM P, Nkoum N, Ceesay A, Mbaye EH, et al
    Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00663.
    >> Share

  293. SHI M, Chen X, Sun Y, Kim HK, et al
    A protein A based Staphylococcus aureus vaccine with improved safety.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00667.
    >> Share

  294. CHYDERIOTIS S, Sicsic J, Raude J, Bonmarin I, et al
    Optimising HPV vaccination communication to adolescents: A discrete choice experiment.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00656.
    >> Share

  295. WANG Y, Zhang Y, Wu H, Huang L, et al
    Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00665.
    >> Share

  296. DEY A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, et al
    Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00706.
    >> Share

  297. PATEL MK, Bergeri I, Bresee JS, Cowling BJ, et al
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00707.
    >> Share

    May 2021
  298. BREWER NT, Mitchell CG, Alton Dailey S, Hora L, et al
    HPV vaccine communication training in healthcare systems: Evaluating a train-the-trainer model.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00610.
    >> Share

  299. ZIPFEL CM, Colizza V, Bansal S
    The missing season: The impacts of the COVID-19 pandemic on influenza.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00635.
    >> Share

  300. LEWIS NS, Banyard AC, Essen S, Whittard E, et al
    Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 influenza A viruses and impact on vaccine use for mitigation and control.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00655.
    >> Share

  301. GREWAL R, Deeks SL, Hart TA, Cox J, et al
    Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00603.
    >> Share

  302. MCGUINNESS D, Kaufhold RM, McHugh PM, Winters MA, et al
    Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00549.
    >> Share

  303. BARDENHEIER BH, Gravenstein S, Blackman C, Gutman R, et al
    Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00683.
    >> Share

  304. ABU MOUCH S, Roguin A, Hellou E, Ishai A, et al
    Myocarditis following COVID-19 mRNA vaccination.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00682.
    >> Share

  305. WAGNER NM, Dempsey AF, Narwaney KJ, Gleason KS, et al
    Addressing logistical barriers to childhood vaccination using an automated reminder system and online resource intervention: A randomized controlled trial.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00639.
    >> Share

  306. SULLIVAN E, Lecollinet S, Kerviel A, Hue E, et al
    Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.
    Vaccine. 2021;39:3161-3168.
    >> Share

  307. BRANDILEONE MC, Almeida SCG, Bokermann S, Minamisava R, et al
    Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019.
    Vaccine. 2021;39:3207-3215.
    >> Share

  308. GURWITZ D
    COVID-19 vaccine hesitancy: Lessons from Israel.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00680.
    >> Share

  309. CHU H, Ko LK, Ibrahim A, Bille Mohamed F, et al
    The impact of an educational forum intervention on East African mothers' HPV vaccine-related knowledge, attitudes, and intentions to vaccinate their adolescent children.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00593.
    >> Share

  310. VUJOVICH-DUNN C, Kaufman J, King C, Skinner SR, et al
    A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00583.
    >> Share

  311. KESSELS R, Luyten J, Tubeuf S
    Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00664.
    >> Share

  312. SATTLER C, Hoffmann P, Herzberg PY, Weber D, et al
    Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis.
    Vaccine. 2021 May 25. pii: S0264-410X(21)00511.
    >> Share

  313. WATESKA AR, Nowalk MP, Jalal H, Lin CJ, et al
    Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Alpha value of information analysis.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00609.
    >> Share

  314. COX SN, Wedlock PT, Pallas SW, Mitgang EA, et al
    A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00605.
    >> Share

  315. VANHEMS P
    A breath of humanity in the era of Covid-19 vaccine.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00638.
    >> Share

  316. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    >> Share

  317. GIDENGIL C, Goetz MB, Newberry S, Maglione M, et al
    Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis.
    Vaccine. 2021 May 23. pii: S0264-410X(21)00385.
    >> Share

  318. NADARZYNSKI T, Frost M, Miller D, Wheldon CW, et al
    Vaccine acceptability, uptake and completion amongst men who have sex with men: A systematic review, meta-analysis and theoretical framework.
    Vaccine. 2021 May 22. pii: S0264-410X(21)00564.
    >> Share

  319. HIRST A, Hyer RN, Janssen RS
    Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00582.
    >> Share

  320. TUFAIL S, Shah MA, Zafar M, Asif TA, et al
    Identification of potent epitopes on hexon capsid protein and their evaluation as vaccine candidates against infections caused by members of Adenoviridae family.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00585.
    >> Share

  321. ARDURA-GARCIA C, Kreis C, Rakic M, Jaboyedoff M, et al
    Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis.
    Vaccine. 2021;39:2917-2928.
    >> Share

  322. BIANCHI FP, Larocca AMV, Bozzi A, Spinelli G, et al
    Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study.
    Vaccine. 2021;39:2989-2994.
    >> Share

  323. VOGEL TP, Top KA, Karatzios C, Hilmers DC, et al
    Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3037-3049.
    >> Share

  324. SERAZIN NA, Edem B, Williams SR, Ortiz JR, et al
    Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3028-3036.
    >> Share

  325. AIZAWA Y, Katsuta T, Sakiyama H, Tanaka-Taya K, et al
    Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00636.
    >> Share

  326. OKORONKWO C, Taiwo LA, Asolo JA, Baptiste AEJ, et al
    Leveraging on the 2017/2018 measles vaccination campaign to improve health workers knowledge and practice on injection safety: A case study of north-central states, Nigeria.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00565.
    >> Share

  327. SON HJ, Lee E, Park SY, Lee S, et al
    Promotion of healthcare personnel vaccinations among newly employed doctors and nurses: Evidence-guided strategy.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00589.
    >> Share

  328. BLANCHARD-ROHNER G, Enriquez N, Lemaitre B, Cadau G, et al
    Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients.
    Vaccine. 2021 May 20. pii: S0264-410X(21)00594.
    >> Share

  329. NICHOLLS LAB, Gallant AJ, Cogan N, Rasmussen S, et al
    Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00544.
    >> Share

  330. DANG JHT, Stewart SL, Blumberg DA, Rodriguez HP, et al
    Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00525.
    >> Share

  331. KIM S, Williams TC, Viboud C, Campbell H, et al
    RSV genomic diversity and the development of a globally effective RSV intervention.
    Vaccine. 2021;39:2811-2820.
    >> Share

  332. NAG K, Chandra Baray J, Rahman Khan M, Mahmud A, et al
    An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00607.
    >> Share

  333. LUK TT, Zhao S, Wu Y, Wong JY, et al
    Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00608.
    >> Share

  334. MENKIR TF, Jbaily A, Verguet S
    Incorporating equity in infectious disease modeling: Case study of a distributional impact framework for measles transmission.
    Vaccine. 2021;39:2894-2900.
    >> Share

  335. GULLA K, Cibelli N, Cooper JW, Fuller HC, et al
    A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00545.
    >> Share

  336. FUKUDA M, Nakamura J, Ito S, Kawazoe K, et al
    Vaccination inhibits the human adenoviral transduction in a mouse keratoconjunctivitis model.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00561.
    >> Share

  337. NAKAHASHI-OUCHIDA R, Uchida Y, Yuki Y, Katakai Y, et al
    A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00552.
    >> Share

  338. CHAN YW, Wong ML, Kwok FY, Au AK, et al
    The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00541.
    >> Share

  339. MCGIRR A, Bourgoin T, Wortzman M, Millson B, et al
    An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00523.
    >> Share

  340. AWAD AM, Ntoso A, Connaire JJ, Hernandez GT, et al
    An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) in adults receiving hemodialysis.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00554.
    >> Share

  341. WOOD RM, Murch BJ, Moss SJ, Tyler JMB, et al
    Operational research for the safe and effective design of COVID-19 mass vaccination centres.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00588.
    >> Share

  342. GUBERNOT D, Jazwa A, Niu M, Baumblatt J, et al
    U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00578.
    >> Share

  343. CHUNG JR, Flannery B, Kim SS, Gaglani M, et al
    Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00555.
    >> Share

  344. WANG J, Jiang L, Zhang C, He W, et al
    The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00560.
    >> Share

  345. LIU Y, Xiong Y, Liang Y, Deng X, et al
    Waning immunity and potential asymptomatic infection in 3-7 years old children who received one dose of measles-mumps-rubella vaccine: A 4-year prospective study.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00559.
    >> Share

  346. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00543.
    >> Share

  347. BANNISTER S, Sudbury E, Villanueva P, Perrett K, et al
    The safety of BCG revaccination: A systematic review.
    Vaccine. 2021;39:2736-2745.
    >> Share

  348. LONGCHAMPS C, Ducarroz S, Crouzet L, Vignier N, et al
    COVID-19 vaccine hesitancy among persons living in homeless shelters in France.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00563.
    >> Share

  349. GROENEWEG L, Loeffen YGT, Versluys AB, Wolfs TFW, et al
    Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00508.
    >> Share

  350. HAN B, Liu W, Du J, Liu H, et al
    Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00540.
    >> Share

  351. KIM TH, Choi JH, Park SH, Yoo JH, et al
    Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged >/= 65 years.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00551.
    >> Share

  352. UWABOR E, Chau V, Romanin C, Loh LC, et al
    Digital tools for vaccine reporting: A perspective from the province of Ontario.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00558.
    >> Share

  353. ARREDONDO JL, Villagomez Martinez SM, Concepcion Morales M, Meyer S, et al
    Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00546.
    >> Share

  354. KRAIGSLEY AM, Moore KA, Bolster A, Peters M, et al
    Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00502.
    >> Share

  355. CHILENGI R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, et al
    Immunogenicity and safety of two monovalent rotavirus vaccine, ROTAVAC(R) and ROTAVAC 5D(R) in Zambian infants.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00542.
    >> Share

  356. GLENN BA, Nonzee NJ, Tieu L, Pedone B, et al
    Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00454.
    >> Share

  357. AFIFI TO, Salmon S, Taillieu T, Stewart-Tufescu A, et al
    Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00590.
    >> Share

  358. LEUNG VKY, Fox A, Carolan LA, Aban M, et al
    Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00483.
    >> Share

  359. POWELL H, Liu H, Pekosz A
    Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00535.
    >> Share

  360. DU QQ, Zeng HL, Yuan L, Tang P, et al
    One cross-sectional investigation revealed that non-vaccine serotypes of Streptococcus pneumoniae could be identified more frequently in elderly Chinese people.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00233.
    >> Share

  361. PASTORINO R, Villani L, La Milia DI, Ieraci R, et al
    Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00566.
    >> Share

  362. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    >> Share

  363. STABEL JR, Bannantine JP
    Reduced tissue colonization of Mycobacterium avium subsp. paratuberculosis in neonatal calves vaccinated with a cocktail of recombinant proteins.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00510.
    >> Share

  364. TANG XY, Yan XX, Wei X, Qin QL, et al
    Timeliness, completeness, and timeliness-and-completeness of serial routine vaccinations among rural children in Southwest China: A multi-stage stratified cluster sampling survey.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00507.
    >> Share

  365. KHALIL I, Walker R, Porter CK, Muhib F, et al
    Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00453.
    >> Share

  366. SOMIYA M, Mine S, Yasukawa K, Ikeda S, et al
    Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00548.
    >> Share

  367. SATOH C, Toizumi M, Nguyen HAT, Hara M, et al
    Prevalence and characteristics of children with otitis media with effusion in Vietnam.
    Vaccine. 2021;39:2613-2619.
    >> Share

  368. MANCA TA, Graham JE, MacDonald NE, Top KA, et al
    Healthcare providers' interpretations of product labelling information developed through a consensus stakeholder approach.
    Vaccine. 2021;39:2652-2659.
    >> Share

  369. CORREIA R, Meneses L, Richheimer C, Alves PM, et al
    Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00480.
    >> Share

  370. FAIRMAN J, Agarwal P, Barbanel S, Behrens C, et al
    Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
    Vaccine. 2021 May 5. pii: S0264-410X(21)00374.
    >> Share

  371. JO CL, Burchett H, Bastias M, Campbell P, et al
    Using existing systematic reviews for developing vaccination recommendations: Results of an international expert workshop.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00504.
    >> Share

  372. WANG J, Bai S, Zhou S, Zhao W, et al
    Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2-5 years in China.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00484.
    >> Share

  373. BITENCOURT J, Sarno A, Oliveira C, Souza RA, et al
    Comparing cytokine production and clinical response following vaccination with BCG Moreau and BCG Russia strains in a Brazilian infant population.
    Vaccine. 2021 May 5. pii: S0264-410X(21)00475.
    >> Share

  374. MILLAR EV, Bennett JW, Barin B, Carey PM, et al
    Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00478.
    >> Share

  375. HALL GC, Douglas I, Heath PT, Prabhakar P, et al
    Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00256.
    >> Share

  376. MPHURU A, Li AJ, Kyesi F, Mwengee W, et al
    National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00472.
    >> Share

  377. OTERI AJ, Adamu U, Dieng B, Bawa S, et al
    Nigeria experience on the use of polio assets for the 2017/18 measles vaccination campaign follow-up.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00497.
    >> Share

  378. LAURENZ M, von Eiff C, Borchert K, Jacob C, et al
    Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change - A claims database analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00476.
    >> Share

  379. TAMANDJOU TCHUEM CR, Andersson MI, Wiysonge CS, Mufenda J, et al
    Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00498.
    >> Share

  380. MANDOMANDO I, Mumba M, Nsiari-Muzeyi Biey J, Kipese Paluku G, et al
    Implementation of the World Health Organization recommendation on the use of rotavirus vaccine without age restriction by African countries.
    Vaccine. 2021 May 3. pii: S0264-410X(21)00289.
    >> Share

  381. YOSHIMURA M, Shinmura Y, Shishido T, Takagi S, et al
    Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys.
    Vaccine. 2021 May 1. pii: S0264-410X(21)00477.
    >> Share

    April 2021
  382. WELSH KJ, Baumblatt J, Chege W, Goud R, et al
    Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00524.
    >> Share

  383. EYAL N, Gerhard T, Strom BL
    Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00526.
    >> Share

  384. ITO S, Nakamura J, Fukuta M, Ura T, et al
    Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00482.
    >> Share

  385. WILKINSON K, Righolt CH, Elliott LJ, Fanella S, et al
    Pertussis vaccine effectiveness and duration of protection - A systematic review and meta-analysis.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00479.
    >> Share

  386. POLKOWSKA A, Rinta-Kokko H, Toropainen M, Palmu AA, et al
    Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland.
    Vaccine. 2021 Apr 29. pii: S0264-410X(21)00186.
    >> Share

  387. KINI A, Morgan R, Kuo H, Shea P, et al
    Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00448.
    >> Share

  388. DIAS HF, Kuhtreiber WM, Nelson KJ, Ng NC, et al
    Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00446.
    >> Share

  389. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    >> Share

  390. SAITOH A, Okabe N
    Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00460.
    >> Share

  391. XU J, Doyon-Plourde P, Tunis M, Quach C, et al
    Effect of early measles vaccination on long-term protection: A systematic review.
    Vaccine. 2021 Apr 26. pii: S0264-410X(21)00447.
    >> Share

  392. KWON JH, Criado MF, Killmaster L, Ali MZ, et al
    Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh.
    Vaccine. 2021 Apr 25. pii: S0264-410X(21)00459.
    >> Share

  393. MACINTYRE CR, Costantino V, Trent M
    Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00501.
    >> Share

  394. KREPS SE, Kriner DL
    Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00503.
    >> Share

  395. PARK MA, Jenkins SM, Smith CY, Pyle RC, et al
    Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00450.
    >> Share

  396. XIRIDOU M, Visser M, Urbanus A, Matser A, et al
    Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00433.
    >> Share

  397. OLATUNJI EA, Ogunsola AS, Khodakarami N, Callaghan T, et al
    Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00451.
    >> Share

  398. SOLANS L, Debrie AS, Coutte L, Locht C, et al
    Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00449.
    >> Share

  399. ROY CHOUDHURY A, Polachek SW
    The impact of paid family leave on the timely vaccination of infants.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00403.
    >> Share

  400. KAWAMURA Y, Hattori F, Higashimoto Y, Kozawa K, et al
    Evaluation of varicella vaccine effectiveness during outbreaks in schools or nurseries by cross-sectional study.
    Vaccine. 2021 Apr 21. pii: S0264-410X(21)00434.
    >> Share

  401. STEVENS NE, van Wolfswinkel M, Bao W, Ryan FJ, et al
    Immunisation with the BCG and DTPw vaccines induces different programs of trained immunity in mice.
    Vaccine. 2021 Apr 21. pii: S0264-410X(21)00400.
    >> Share

  402. HAMISU M, Dieng B, Taiwo L, Jean Baptiste AE, et al
    Microplanning verification and 2017/2018 measles vaccination campaign in Nigeria: Lessons learnt.
    Vaccine. 2021 Apr 20. pii: S0264-410X(21)00432.
    >> Share

  403. PIERSON BC, Cardile AP, Okwesili AC, Downs IL, et al
    Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine.
    Vaccine. 2021 Apr 19. pii: S0264-410X(21)00309.
    >> Share

  404. JEAN BAPTISTE AE, Masresha B, Wagai J, Luce R, et al
    Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018.
    Vaccine. 2021 Apr 17. pii: S0264-410X(21)00424.
    >> Share

  405. SAVAGE RD, Bell CA, Righolt CH, Wilkinson K, et al
    A multisite study of pertussis vaccine effectiveness by time since last vaccine dose from three Canadian provinces: A Canadian Immunization Research Network study.
    Vaccine. 2021 Apr 16. pii: S0264-410X(21)00310.
    >> Share

  406. OSTOLIN TLVDP, Gusmao MR, Mathias FAS, Cardoso JMO, et al
    A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Vaccine. 2021 Apr 16. pii: S0264-410X(21)00429.
    >> Share

  407. MARTIN JC, Petrecz ML, Stek JE, Simon JK, et al
    Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA).
    Vaccine. 2021 Apr 15. pii: S0264-410X(21)00345.
    >> Share

  408. GUZMAN-HOLST A, Luna-Casas G, Cervantes-Apolinar MY, Huerta-Garcia GC, et al
    Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: An ecological database study with time-series analysis.
    Vaccine. 2021;39:2311-2318.
    >> Share

  409. YAMADA M, Li M, Iino T
    Pneumococcal vaccine coverage in Japan among patients with a history of splenectomy: Results of a retrospective administrative database study.
    Vaccine. 2021 Apr 14. pii: S0264-410X(21)00338.
    >> Share

  410. DANIEL M, Liang B, Luo M
    Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00372.
    >> Share

  411. BROOK B, Schaltz-Buchholzer F, Ben-Othman R, Kollmann T, et al
    A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00408.
    >> Share

  412. LEVIN Y, Balakirski NM, Caraco Y, Ben-Ami E, et al
    Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00452.
    >> Share

  413. WANG C, Han B, Zhao T, Liu H, et al
    Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00455.
    >> Share

  414. YU Q, Li X, Fan M, Qiu H, et al
    The impact of childhood pneumococcal conjugate vaccine immunisation on all-cause pneumonia admissions in Hong Kong: A 14-year population-based interrupted time series analysis.
    Vaccine. 2021 Apr 12. pii: S0264-410X(21)00406.
    >> Share

  415. PRYMULA R, Povey M, Brzostek J, Cabrnochova H, et al
    Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Vaccine. 2021 Apr 12. pii: S0264-410X(21)00401.
    >> Share

  416. CHOI SK, Baik YO, Kim CW, Kim SK, et al
    An open-label, comparative, single dose, clinical Phase study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
    Vaccine. 2021 Apr 10. pii: S0264-410X(21)00405.
    >> Share

  417. LA EM, Garbinsky D, Hunter S, Poston S, et al
    Meningococcal B vaccination coverage among older adolescents in the United States.
    Vaccine. 2021 Apr 10. pii: S0264-410X(21)00375.
    >> Share

  418. HAMILTON RA, Krockow EM, Vekria P
    Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00407.
    >> Share

  419. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    >> Share

  420. PU J, Yu Q, Yin Z, Zhang Y, et al
    The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00431.
    >> Share

  421. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    >> Share

  422. HOGAN AB, Winskill P, Watson OJ, Walker PGT, et al
    Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00427.
    >> Share

  423. CEYHAN M, Karadag-Oncel E, Hascelik G, Ustundag G, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children aged less than five years.
    Vaccine. 2021;39:2041-2047.
    >> Share

  424. PAGLIUSI S, Hayman B, Jarrett S
    Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Vaccine. 2021 Apr 7. pii: S0264-410X(21)00293.
    >> Share

  425. GRAMACHO WG, Turgeon M
    When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00396.
    >> Share

  426. HATZIANTONIOU S, Maltezou HC, Tsakris A, Poland GA, et al
    Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00377.
    >> Share

  427. DANIELS V, Saxena K, Roberts C, Kothari S, et al
    Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00428.
    >> Share

  428. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    >> Share

  429. DION SB, Major M, Gabriela Grajales A, Nepal RM, et al
    Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00260.
    >> Share

  430. DONG TQ, Wakefield J
    Modeling and presentation of vaccination coverage estimates using data from household surveys.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00275.
    >> Share

  431. STALPERS CAL, Retmana IA, Pennings JLA, Vandebriel RJ, et al
    Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines.
    Vaccine. 2021 Apr 3. pii: S0264-410X(21)00384.
    >> Share

  432. YAO T, Shao Z, Wu L, Dong S, et al
    Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China.
    Vaccine. 2021 Apr 2. pii: S0264-410X(21)00378.
    >> Share

  433. BEZERRA FSB, Silva MTO, Rezende AFS, Lopes AS, et al
    Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00366.
    >> Share

  434. DE MIRANDA LOPES KA, Baptista PN, de Medeiros Nascimento R, Pimentel A, et al
    Clinical repercussions in pertussis infants post-Tdpa vaccination of pregnant woman: An immunization success?
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00373.
    >> Share

  435. SUH J, Lee T, Choi JK, Lee J, et al
    The impact of two-dose varicella vaccination on varicella and herpes zoster incidence in South Korea using a mathematical model with changing population demographics.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00349.
    >> Share

  436. CARR DJJ, Berube AN, Filiberti A, Gmyrek GB, et al
    Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0DeltaNLS vaccine against ocular HSV-1 challenge.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00379.
    >> Share

  437. HOFFMAN BL, Colditz JB, Shensa A, Wolynn R, et al
    #DoctorsSpeakUp: Lessons learned from a pro-vaccine Twitter event.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00365.
    >> Share

  438. CROWCROFT NS, Bolotin S, Li Y, Campbell H, et al
    Infant pertussis and maternal immunity: The curious case of Canada.
    Vaccine. 2021;39:1977-1981.
    >> Share

  439. AMIN-CHOWDHURY Z, Groves N, Sheppard CL, Litt D, et al
    Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Vaccine. 2021;39:1997-2004.
    >> Share

  440. QUAN DH, Counoupas C, Nagalingam G, Pinto R, et al
    Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity.
    Vaccine. 2021;39:1990-1996.
    >> Share

    March 2021
  441. ERIKSSON M, Kayhty H, Lahdenkari M, Makisalo H, et al
    A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
    Vaccine. 2021 Mar 31. pii: S0264-410X(21)00367.
    >> Share

  442. KLOUWENS MJ, Salverda MLM, Trentelman JJ, Ersoz JI, et al
    Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Vaccine. 2021 Mar 31. pii: S0264-410X(21)00363.
    >> Share

  443. AZZI L, Focosi D, Dentali F, Baj A, et al
    Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00402.
    >> Share

  444. CHEN H, Gao Z, Bai S, Liu X, et al
    Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00264.
    >> Share

  445. PELTON SI, Divino V, Postma MJ, Shah D, et al
    A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00347.
    >> Share

  446. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    >> Share

  447. YAMAWAKI RA, Rubio MDS, Alves LBR, de Almeida AM, et al
    Evaluation of transfer of maternal immunity to the offspring of broiler breeders vaccinated with a candidate recombinant vaccine against Salmonella Enteritidis.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00343.
    >> Share

  448. BAVANANTHASIVAM J, Alizadeh M, Astill J, Alqazlan N, et al
    Effects of administration of probiotic lactobacilli on immunity conferred by the herpesvirus of turkeys vaccine against challenge with a very virulent Marek's disease virus in chickens.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00339.
    >> Share

  449. WIJAYANTI KE, Schutze H, MacPhail C, Braunack-Mayer A, et al
    Parents' knowledge, beliefs, acceptance and uptake of the HPV vaccine in members of The Association of Southeast Asian Nations (ASEAN): A systematic review of quantitative and qualitative studies.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00342.
    >> Share

  450. KUTER BJ, Offit PA, Poland GA
    The development of COVID-19 vaccines in the United States: Why and how so fast?
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00383.
    >> Share

  451. RUSSO AG, Decarli A, Valsecchi MG
    Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00382.
    >> Share

  452. LAMPONEN T, Hetemaki I, Niemi HJ, Jarva H, et al
    Heterologous boosting of nonrelated toxoid immunity during acute Puumala hantavirus infection.
    Vaccine. 2021;39:1818-1825.
    >> Share

  453. VREMAN S, Rebel JMJ, McCaffrey J, Ledl K, et al
    Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs.
    Vaccine. 2021;39:1857-1869.
    >> Share

  454. WAN C, Gao C, Xie Q, Wang Y, et al
    Flagella hook protein FlgE is a novel vaccine candidate of Pseudomonas aeruginosa identified by a genomic approach.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00344.
    >> Share

  455. NGUYEN KH, Santibanez TA, Stokley S, Lindley MC, et al
    Parental vaccine hesitancy and its association with adolescent HPV vaccination.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00341.
    >> Share

  456. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    >> Share

  457. MPHAHLELE MJ, Groome MJ, Page NA, Bhagwandin N, et al
    A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12(th) African Rotavirus Symposium.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00282.
    >> Share

  458. SALMON DA, Dudley MZ, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00315.
    >> Share

  459. MURRAY SM, McKay PF
    Chlamydia trachomatis: Cell biology, immunology and vaccination.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00326.
    >> Share

  460. BEISSBARTH J, Wilson N, Arrowsmith B, Binks MJ, et al
    Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00311.
    >> Share

  461. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    >> Share

  462. HAEDER SF
    Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00348.
    >> Share

  463. ANGELIS A, Darrow J
    Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00346.
    >> Share

  464. KOCHHAR S, Dube E, Graham J, Jee Y, et al
    COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00364.
    >> Share

  465. ZHANG Y, Li D, Zhao H, Wang L, et al
    The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00371.
    >> Share

  466. ANTONELLI INCALZI R, Trevisan C, Del Signore S, Volpato S, et al
    Are vaccines against COVID-19 tailored to the most vulnerable people?
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00370.
    >> Share

  467. KENDAL A
    Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00283.
    >> Share

  468. CHEN D, Ye Z, Pi Z, Mizukami S, et al
    Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00324.
    >> Share

  469. VILCHES TN, Zhang K, Van Exan R, Langley JM, et al
    Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00362.
    >> Share

  470. ARTENSTEIN AW
    A half-century of meningococcal vaccines.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00292.
    >> Share

  471. EL BARA A, Pivert A, Veillon P, Ng Wing Sang C, et al
    From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00279.
    >> Share

  472. ZHANG Z, Pan J, Chen M, Zhang T, et al
    Seroepidemiology of pertussis in China: A population-based, cross-sectional study.
    Vaccine. 2021;39:1687-1692.
    >> Share

  473. RANE MS, Page LC, McVeigh E, Miller K, et al
    Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns.
    Vaccine. 2021;39:1765-1772.
    >> Share

  474. KHANNA M, Rady H, Dai G, Ramsay AJ, et al
    Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Vaccine. 2021;39:1780-1787.
    >> Share

  475. TEMPLE B, Nation ML, Dai VTT, Beissbarth J, et al
    Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam.
    Vaccine. 2021 Mar 18. pii: S0264-410X(21)00223.
    >> Share

  476. NWOGU IB, Jones M, Langley T
    Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
    Vaccine. 2021 Mar 18. pii: S0264-410X(21)00229.
    >> Share

  477. BROWN DR, Joura EA, Yen GP, Kothari S, et al
    Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence.
    Vaccine. 2021 Mar 17. pii: S0264-410X(20)31564.
    >> Share

  478. PHUA LC, Choi HCW, Wu J, Jit M, et al
    Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00321.
    >> Share

  479. AGOCS M, Ismail A, Kamande K, Tabu C, et al
    Reasons why children miss vaccinations in Western Kenya; A step in a five-point plan to improve routine immunization.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00262.
    >> Share

  480. CAMBOU MC, Copeland TP, Nielsen-Saines K, Macinko J, et al
    Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00294.
    >> Share

  481. HAMIDI A, Hoeksema F, Velthof P, Lemckert A, et al
    Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00312.
    >> Share

  482. UEKI S, Matsunaka E, Takao K, Kitao M, et al
    The effectiveness of vibratory stimulation in reducing pain in children receiving vaccine injection: A randomized controlled trial.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00281.
    >> Share

  483. SZIGETI R, Kellermayer R
    Natural unblinding of BCG vaccination trials.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00320.
    >> Share

  484. GRAUPENSPERGER S PHD, Abdallah DA, Lee CM
    Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00286.
    >> Share

  485. STEIMLE LN, Havumaki J, Eisenberg MC, Eisenberg JNS, et al
    Cost-effectiveness of pediatric norovirus vaccination in daycare settings.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00257.
    >> Share

  486. SUSARLA SK, Palkar S, Sv PS, Diwan A, et al
    Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00280.
    >> Share

  487. DEERIN JF, Clifton R, Elmi A, Lewis PE, et al
    Hepatitis B birth dose vaccination patterns in the military health System, 2014-2018.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00278.
    >> Share

  488. ALLINGTON D, McAndrew S, Moxham-Hall VL, Duffy B, et al
    Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00234.
    >> Share

  489. CHOI UY, Kim KH, Lee KY, Kim JH, et al
    Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00273.
    >> Share

  490. HARRISON GBL, Heath DD, Robinson CM, Lawrence SB, et al
    Combined use of two separate but protective vaccine antigens provides protection against Taenia ovis infection in lambs in the presence of protective maternal antibody.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00308.
    >> Share

  491. MOLODECKY NA, Usman A, Javaid A, Wahdan A, et al
    Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00269.
    >> Share

  492. HABIB MA, Prymula R, Carryn S, Esposito S, et al
    Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00265.
    >> Share

  493. NET P, Colrat F, Nascimento Costa M, Bianic F, et al
    Estimating public health and economic benefits along 10 years of Fluzone(R) High Dose in the United States.
    Vaccine. 2021;39 Suppl 1:A56-A69.
    >> Share

  494. FERREIRA MN, Netto EM, Nascimento-Carvalho CM
    The impact of 10-valent pneumococcal conjugate vaccine upon hospitalization rate of children with pneumonia in different Brazilian administrative regions.
    Vaccine. 2021 Mar 14. pii: S0264-410X(21)00231.
    >> Share

  495. WILLIAMSON JD, Gould KG, Brown K
    Richard Pfeiffer's typhoid vaccine and Almroth Wright's claim to priority.
    Vaccine. 2021 Mar 13. pii: S0264-410X(21)00285.
    >> Share

  496. RIGHOLT CH, Pabla G, Donelle J, Brna P, et al
    Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network study.
    Vaccine. 2021 Mar 13. pii: S0264-410X(21)00277.
    >> Share

  497. BUTTERY JP
    Developing standard safety outcomes for COVID-19 vaccines.
    Vaccine. 2021 Mar 12. pii: S0264-410X(21)00272.
    >> Share

  498. THANAWASTIEN A, Joyce KE, Cartee RT, Haines LA, et al
    Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.
    Vaccine. 2021;39:1652-1660.
    >> Share

  499. LEE J, Li Y, Li Y, Cino-Ozuna AG, et al
    Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00268.
    >> Share

  500. BERTRAN K, Kassa A, Criado MF, Nunez IA, et al
    Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00266.
    >> Share

  501. EBAMA MS, Chu SY, Azziz-Baumgartner E, Lafond KE, et al
    Ancillary benefits of seasonal influenza vaccination in middle-income countries.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00228.
    >> Share

  502. GBENEWEI E, Nomhwange T, Taiwo L, Ayodeji I, et al
    Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00258.
    >> Share

  503. MOMOH J, Oteri AJ, Mogekwu F, Onwu N, et al
    Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00259.
    >> Share

  504. REPERANT LA, Osterhaus ADME
    COVID-19 vaccination and critical care capacity: Perilous months ahead.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00316.
    >> Share

  505. WENTZELL E, Racila AM
    The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00317.
    >> Share

  506. LATKIN C, Dayton LA, Yi G, Konstantopoulos A, et al
    COVID-19 vaccine intentions in the United States, a social-ecological framework.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00238.
    >> Share

  507. KWAK BO, Kwon YS, Hong YJ, Shin SH, et al
    Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00267.
    >> Share

  508. STEFFEN CA, Henaff L, Durupt A, Omeiri NE, et al
    Evidence-informed vaccination decision-making in countries: Progress, challenges and opportunities.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00235.
    >> Share

  509. GATWOOD J, Chiu CY, Shuvo S, Ramachandran S, et al
    Role of social determinants of health in pneumococcal vaccination among high-risk adults.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00241.
    >> Share

  510. GUIDRY JPD, Perrin PB, Laestadius LI, Vraga EK, et al
    U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00306.
    >> Share

  511. MINTA AA, Silva MWT, Shrestha A, de Quiroz-Castro M, et al
    Hepatitis B surface antigen seroprevalence among children in the Philippines, 2018.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00222.
    >> Share

  512. SADARANGANI M, Abu Raya B, Conway JM, Iyaniwura SA, et al
    Importance of COVID-19 vaccine efficacy in older age groups.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00288.
    >> Share

  513. KISZEWSKI AE, Cleary EG, Jackson MJ, Ledley FD, et al
    NIH funding for vaccine readiness before the COVID-19 pandemic.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00290.
    >> Share

  514. PULLAN S, Dey M
    Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00287.
    >> Share

  515. DONADEL M, Panero MS, Ametewee L, Shefer AM, et al
    National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00239.
    >> Share

  516. WILLIAMSON SL, Gadd E, Pillay T, Toldi G, et al
    Non-specific effects of BCG vaccination on neutrophil and lymphocyte counts of healthy neonates from a developed country.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00255.
    >> Share

  517. HASNAN S, Tan NC
    Multi-domain narrative review of vaccine hesitancy in childhood.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00237.
    >> Share

  518. BLACK SB, Law B, Chen RT, Dekker CL, et al
    The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00284.
    >> Share

  519. PIRAS-DOUCE F, Raynal F, Raquin A, Girerd-Chambaz Y, et al
    Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00200.
    >> Share

  520. YOKOMICHI H, Kojima R, Horiuchi S, Ooka T, et al
    Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00224.
    >> Share

  521. DU Y, Xu Y, Feng J, Hu L, et al
    Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00274.
    >> Share

  522. KUO H, Shapiro JR, Dhakal S, Morgan R, et al
    Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00227.
    >> Share

  523. WOO EJ, Moro PL
    Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00232.
    >> Share

  524. STURM L, Kasting ML, Head KJ, Hartsock JA, et al
    Influenza vaccination in the time of COVID-19: A national U.S. survey of adults.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00271.
    >> Share

  525. HELMKAMP LJ, Szilagyi PG, Zimet G, Saville AW, et al
    A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00206.
    >> Share

  526. JOURA EA, Ulied A, Vandermeulen C, Rua Figueroa M, et al
    Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45years of age compared to women 16-26years of age: An open-label phase 3 study.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00128.
    >> Share

  527. WENDLAND EM, Kops NL, Bessel M, Comerlato J, et al
    Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00207.
    >> Share

  528. FELL DB, Dimitris MC, Hutcheon JA, Ortiz JR, et al
    Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00261.
    >> Share

  529. CUTTS FT, Danovaro-Holliday MC, Rhoda DA
    Challenges in measuring supplemental immunization activity coverage among measles zero-dose children.
    Vaccine. 2021;39:1359-1363.
    >> Share

  530. WANG Y, Huang C, Tang J, Liu G, et al
    Salmonella Pullorum spiC mutant is a desirable LASV candidate with proper virulence, high immune protection and easy-to-use oral administration.
    Vaccine. 2021;39:1383-1391.
    >> Share

    February 2021
  531. STANLEY M, Joura E, Yen GP, Kothari S, et al
    Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
    Vaccine. 2021 Feb 28. pii: S0264-410X(21)00099.
    >> Share

  532. WANG J, Lyu Y, Zhang H, Jing R, et al
    Willingness to pay and financing preferences for COVID-19 vaccination in China.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00240.
    >> Share

  533. SHEN M, Zu J, Fairley CK, Pagan JA, et al
    Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00236.
    >> Share

  534. BERNSTEIN DN, Alokozai A, Humbyrd CJ
    Vaccinating America's children: A job for orthopaedic surgeons & other non-primary care specialists?
    Vaccine. 2021 Feb 26. pii: S0264-410X(21)00175.
    >> Share

  535. AYASSE M, Ahmed A, McCullum C, Espinosa ML, et al
    Vaccines do not cause atopic dermatitis: A systematic review and meta-analysis.
    Vaccine. 2021 Feb 26. pii: S0264-410X(21)00203.
    >> Share

  536. WON H, Kim AR, Yoo JS, Chung GT, et al
    Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00055.
    >> Share

  537. ANDERSEN AR, Kolmos SK, Flanagan KL, Benn CS, et al
    Systematic review and meta-analysis of the effect of pertussis vaccine in pregnancy on the risk of chorioamnionitis, non-pertussis infectious diseases and other adverse pregnancy outcomes.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00166.
    >> Share

  538. SPENCER JA, Penfound T, Salehi S, Aranha MP, et al
    Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00129.
    >> Share

  539. SANDBRINK JB, Koblentz GD
    Biosecurity risks associated with vaccine platform technologies.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00171.
    >> Share

  540. LEE MHP, Tan CW, Tee HK, Ong KC, et al
    Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00172.
    >> Share

  541. SELL TK, Gastfriend D, Watson M, Watson C, et al
    Building the global vaccine manufacturing capacity needed to respond to pandemics.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00165.
    >> Share

  542. MUNOZ FM, Cramer JP, Dekker CL, Dudley MZ, et al
    Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00094.
    >> Share

  543. ALDAKAK L, Huber VM, Ruhli F, Bender N, et al
    Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00170.
    >> Share

  544. BONANNI P, Villani A, Scotti S, Biasci P, et al
    The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies.
    Vaccine. 2021;39:1183-1186.
    >> Share

  545. VERELST F, Beutels P, Hens N, Willem L, et al
    Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
    Vaccine. 2021 Feb 22. pii: S0264-410X(21)00168.
    >> Share

  546. SU QD, Zou YN, Yi Y, Shen LP, et al
    Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Vaccine. 2021;39:1241-1247.
    >> Share

  547. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.
    Vaccine. 2021;39:1248-1256.
    >> Share

  548. CHOI UY, Kim KH, Lee J, Eun BW, et al
    Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
    Vaccine. 2021 Feb 21. pii: S0264-410X(21)00161.
    >> Share

  549. REN S, Attia J, Li SC, Newby D, et al
    Pneumococcal polysaccharide vaccine is a cost saving strategy for prevention of acute coronary syndrome.
    Vaccine. 2021 Feb 21. pii: S0264-410X(21)00167.
    >> Share

  550. MCPHERSON AS, Whittington RJ, Hall E, Cook EJ, et al
    A comparison of multivalent and bivalent vaccination strategies for the control of virulent ovine footrot.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00159.
    >> Share

  551. KABIR A, Newall AT, Randall D, Menzies R, et al
    Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00163.
    >> Share

  552. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    >> Share

  553. SAUER M, Vasudevan P, Meghani A, Luthra K, et al
    Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00107.
    >> Share

  554. CHOI J, Jo HJ, Jung SS, Choi J, et al
    Evaluation of swine protection with foot-and-mouth disease O1/Campos and O/Primorsky/2014 vaccines against the O Mya-98 lineage virus from East Asia.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00173.
    >> Share

  555. ORTIZ JR, Robertson J, Hsu JS, Yu SL, et al
    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00204.
    >> Share

  556. DENG L, Danchin M, Lewis G, Cheung A, et al
    Revaccination outcomes of children with vaccine proximate seizures.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00164.
    >> Share

  557. MARTINON-TORRES F, Halperin SA, Nolan T, Tapiero B, et al
    Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00130.
    >> Share

  558. CHANG LJ, Anderson EJ, Jeanfreau R, He Y, et al
    Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6months through<18years of age: A randomized controlled phase II dose-finding trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00162.
    >> Share

  559. CONSTANTINOU CA, Ziogas DC, Venetsanopoulou A, Gamaletsou MN, et al
    A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness.
    Vaccine. 2021 Feb 17. pii: S0264-410X(21)00157.
    >> Share

  560. PALMU AA, De Wals P, Toropainen M, Ladhani SN, et al
    Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.
    Vaccine. 2021 Feb 17. pii: S0264-410X(21)00111.
    >> Share

  561. KUTER BJ, Browne S, Momplaisir FM, Feemster KA, et al
    Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia.
    Vaccine. 2021 Feb 16. pii: S0264-410X(21)00185.
    >> Share

  562. JUSTE RA, Geijo MV, Elguezabal N, Sevilla IA, et al
    Paratuberculosis vaccination specific and non-specific effects on cattle lifespan.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00097.
    >> Share

  563. WU MJ, Chung JR, Kim SS, Jackson ML, et al
    Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00106.
    >> Share

  564. TZANAKAKI G, Xirogianni A, Tsitsika A, Clark SA, et al
    Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Vaccine. 2021 Feb 14. pii: S0264-410X(21)00127.
    >> Share

  565. RID A, Shah SK, Miller FG, Danis M, et al
    Ethical trade-offs in vaccine development and distribution-Response to Gurwitz.
    Vaccine. 2021;39:1028-1029.
    >> Share

  566. GURWITZ D
    Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries.
    Vaccine. 2021;39:1027.
    >> Share

  567. MCALISTER SM, van den Biggelaar AHJ, Woodman TL, Hutton H, et al
    An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
    Vaccine. 2021 Feb 12. pii: S0264-410X(21)00068.
    >> Share

  568. NICACIO AAMF, Peracchi OAB, Yamada J, Fraga MM, et al
    Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
    Vaccine. 2021;39:1165-1172.
    >> Share

  569. HAI NM, Dung ND, Pho DC, Son VT, et al
    Immunogenicity, safety and reactogenicity of ROTAVAC(R) in healthy infants aged 6-8 weeks in Vietnam.
    Vaccine. 2021;39:1140-1147.
    >> Share

  570. DOCKRELL HM, Butkeviciute E
    Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
    Vaccine. 2021 Feb 11. pii: S0264-410X(21)00109.
    >> Share

  571. KHETSURIANI N, Zaika O, Chitadze N, Slobodianyk L, et al
    Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017.
    Vaccine. 2021 Feb 11. pii: S0264-410X(21)00133.
    >> Share

  572. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00108.
    >> Share

  573. WARD BJ, Seguin A, Couillard J, Trepanier S, et al
    Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00004.
    >> Share

  574. POLAND CM, Matthews AKS, Poland GA
    Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00154.
    >> Share

  575. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Corrigendum to "Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance" [Vaccine 38(43) (2020) 6757-6765].
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00105.
    >> Share

  576. CHU L, McPhee R, Huang W, Bennett H, et al
    A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00153.
    >> Share

  577. VULPE SN, Rughinis C
    Social amplification of risk and "probable vaccine damage": A typology of vaccination beliefs in 28 European countries.
    Vaccine. 2021 Feb 8. pii: S0264-410X(21)00102.
    >> Share

  578. SINGH A
    Why not the 'marker' or DIVA vaccines for the control of emerging infectious diseases of humans?
    Vaccine. 2021 Feb 8. pii: S0264-410X(21)00110.
    >> Share

  579. ROBINSON E, Jones A, Lesser I, Daly M, et al
    International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.
    Vaccine. 2021 Feb 6. pii: S0264-410X(21)00140.
    >> Share

  580. BAUER BU, Knittler MR, Prufer TL, Wolf A, et al
    Humoral immune response to Q fever vaccination of three sheep flocks naturally pre-infected with Coxiella burnetii.
    Vaccine. 2021 Feb 5. pii: S0264-410X(21)00101.
    >> Share

  581. DUDLEY MZ, Taitel MS, Smith-Ray R, Singh T, et al
    Effect of educational and financial incentive-based interventions on immunization attitudes, beliefs, intentions and receipt among close contacts of pregnant women.
    Vaccine. 2021;39:961-967.
    >> Share

  582. HODGKINSON B, Wang T, Byrnes J, Scuffham P, et al
    Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review.
    Vaccine. 2021 Feb 4. pii: S0264-410X(21)00100.
    >> Share

  583. SPANOS KE, Kraschnewski JL, Moss JL, Wong A, et al
    Parent support for social media standards combatting vaccine misinformation.
    Vaccine. 2021 Feb 4. pii: S0264-410X(21)00005.
    >> Share

  584. PINPATHOMRAT N, Bull N, Pasricha J, Harrington-Kandt R, et al
    Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.
    Vaccine. 2021 Feb 3. pii: S0264-410X(21)00050.
    >> Share

  585. DIACO M, Chang LJ, Seet B, Robertson CA, et al
    Introductory paper: High dose influenza vaccine.
    Vaccine. 2021 Feb 3. pii: S0264-410X(20)31147.
    >> Share

  586. BABAKURA B, Nomhwange T, Jean Baptiste AE, Dede O, et al
    The challenges of insecurity on implementing vaccination campaign and its effect on measles elimination and control efforts: A case study of 2017/18 measles campaign in Borno state, Nigeria.
    Vaccine. 2021 Feb 2. pii: S0264-410X(21)00040.
    >> Share

  587. SATO R, Thompson A, Sani I, Metiboba L, et al
    Effect of Vaccine Direct Delivery (VDD) on vaccine stockouts and number of vaccinations: Case study from Bauchi State, Nigeria.
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00053.
    >> Share

  588. GAO J, Tang F, Wang Z, Yu J, et al
    Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019.
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00075.
    >> Share

  589. WILCK MB, Jin Xu Z, Stek JE, Goveia MG, et al
    Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS).
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00073.
    >> Share

    January 2021
  590. AXELSEN PH, Poland GA
    Vaccines, masks, distancing and credibility: An urgent warning for pandemic management.
    Vaccine. 2021 Jan 31. pii: S0264-410X(21)00079.
    >> Share

  591. LIU Y, Li W, Dong Q, Chen M, et al
    Non-linear relationships between children age and pneumococcal vaccine coverage: Important implications for vaccine prevention strategies.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00095.
    >> Share

  592. LUANGASANATIP N, Mahikul W, Poovorawan K, Cooper BS, et al
    Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00078.
    >> Share

  593. D'ARCO C, McCormick AA, Arnaboldi PM
    Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
    Vaccine. 2021 Jan 30. pii: S0264-410X(21)00067.
    >> Share

  594. ANDANI A, van Damme P, Bunge EM, Salgado F, et al
    One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00054.
    >> Share

  595. XU W, Yang M
    Genetic variation and evolution of foot-and-mouth disease virus serotype A in relation to vaccine matching.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00069.
    >> Share

  596. COLRAT F, Thommes E, Largeron N, Alvarez FP, et al
    Economic evaluation of high-dose inactivated influenza vaccine in adults aged >/=65 years: A systematic literature review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(20)31603.
    >> Share

  597. HAMPTON LM, Aggarwal R, Evans SJW, Law B, et al
    General determination of causation between Covid-19 vaccines and possible adverse events.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00096.
    >> Share

  598. KROLIK M, Csepregi L, Hartmann F, Engetschwiler C, et al
    Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.
    Vaccine. 2021 Jan 28. pii: S0264-410X(21)00074.
    >> Share

  599. SORUP S, Englund H, Laake I, Nieminen H, et al
    Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
    Vaccine. 2021 Jan 28. pii: S0264-410X(21)00044.
    >> Share

  600. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    >> Share

  601. LI AJ, Kyesi F, Mwengee W, Mphuru A, et al
    Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00052.
    >> Share

  602. LY TDA, Castaneda S, Hoang VT, Dao TL, et al
    Vaccine-preventable diseases other than tuberculosis, and homelessness: A scoping review of the published literature, 1980 to 2020.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00051.
    >> Share

  603. JONSSON G, Hansson C, Mellhammar L, Gullstrand B, et al
    Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00007.
    >> Share

  604. BELCHER T, Kammoun H, Coutte L, Debrie AS, et al
    Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice.
    Vaccine. 2021 Jan 25. pii: S0264-410X(21)00041.
    >> Share

  605. KIM SH, Paldurai A, Xiao S, Collins PL, et al
    Retraction notice to "Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens" [Vaccine 32(35) (2014) 4428-4435].
    Vaccine. 2021;39:775.
    >> Share

  606. KNOBEL DL, Arega SM, Conan A
    Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00045.
    >> Share

  607. AMANI A, Tatang CA, Bayiha CN, Woung M, et al
    A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00021.
    >> Share

  608. HUTTON DW, McCullough JS, Prosser L, Ye W, et al
    Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31535.
    >> Share

  609. OKOLI GN, Racovitan F, Abdulwahid T, Righolt CH, et al
    Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studie
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00048.
    >> Share

  610. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    >> Share

  611. JAMROZIK E, Littler K, Bull S, Emerson C, et al
    Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Vaccine. 2021;39:633-640.
    >> Share

  612. MENZIES R, Stein AN, Booy R, Van Buynder PG, et al
    The impact of the changing pneumococcal national immunisation program among older Australians.
    Vaccine. 2021;39:720-728.
    >> Share

  613. COX AD, Kuo Lee R, Ulanova M, Bruce MG, et al
    Proceedings of a workshop to discuss the epidemiology of invasive Haemophilus influenzae disease with emphasis on serotype a and b in the Americas, 2019.
    Vaccine. 2021;39:627-632.
    >> Share

  614. JIANG R, Liu X, Sun X, Wang J, et al
    Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00043.
    >> Share

  615. KLASSEN AC, Milliron BJ, Reynolds L, Bakhtibekova Z, et al
    Formative research to address vaccine hesitancy in Tajikistan.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00049.
    >> Share

  616. ALDRICH C, Leroux-Roels I, Huang KB, Bica MA, et al
    Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
    Vaccine. 2021 Jan 21. pii: S0264-410X(20)31667.
    >> Share

  617. NIYIBITEGEKA F, Riewpaiboon A, Youngkong S, Thavorncharoensap M, et al
    Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00047.
    >> Share

  618. HAYMAN B, Bowles A, Evans B, Eyermann E, et al
    Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.
    Vaccine. 2021 Jan 21. pii: S0264-410X(21)00009.
    >> Share

  619. POLAND EG, McGuire DK, Ratishvili T, Poland GA, et al
    The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31694.
    >> Share

  620. WINOKUR P, El Sahly HM, Mulligan MJ, Frey SE, et al
    Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31504.
    >> Share

  621. JAS D, Frances-Duvert V, Brunet S, Oberli F, et al
    Evaluation of safety and immunogenicity of feline vaccines with reduced volume.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00042.
    >> Share

  622. MUGO N, Eckert LO, Odero L, Gakuo S, et al
    Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31587.
    >> Share

  623. BALASUBRAMANI GK, Zimmerman RK, Eng H, Lyons J, et al
    Comparison of local influenza vaccine effectiveness using two methods.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00017.
    >> Share

  624. DAL-RE R
    US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00077.
    >> Share

  625. LOIACONO MM, Pool V, van Aalst R
    DTaP combination vaccine use and adherence: A retrospective cohort study.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00013.
    >> Share

  626. CAO L, Lou J, Zhao S, Chan RWY, et al
    In silico prediction of influenza vaccine effectiveness by sequence analysis.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00006.
    >> Share

  627. EINARSDOTTIR S, Nicklasson M, Veje M, Bergstrom T, et al
    Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation.
    Vaccine. 2021 Jan 19. pii: S0264-410X(20)31670.
    >> Share

  628. BROCATO RL, Kwilas SA, Josleyn MD, Long S, et al
    Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00002.
    >> Share

  629. REEMERS S, Verstegen I, Basten S, Hubers W, et al
    A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00022.
    >> Share

  630. FATOBA AJ, Maharaj L, Adeleke VT, Okpeku M, et al
    Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00003.
    >> Share

  631. SCOTT EM, Stein R, Brown MF, Hershberger J, et al
    Vaccination patterns of the northeast Ohio Amish revisited.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00026.
    >> Share

  632. OTERI J, Idi Hussaini M, Bawa S, Ibizugbe S, et al
    Application of the Geographic Information System (GIS) in immunisation service delivery; its use in the 2017/2018 measles vaccination campaign in Nigeria.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00025.
    >> Share

  633. SOHN S, Hong K, Hwang H, Chun BC, et al
    Paradoxical health care utilization patterns among children in Korea who did not receive mandatory pneumococcal vaccination.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00016.
    >> Share

  634. XU C, Lau CL, Clark J, Rafferty AC, et al
    Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00039.
    >> Share

  635. WHITAKER JA, Parikh SA, Shanafelt TD, Kay NE, et al
    The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Vaccine. 2021 Jan 15. pii: S0264-410X(21)00001.
    >> Share

  636. MOGEKWU FI, Oteri JA, Nsubuga P, Ezebilo O, et al
    Using data to improve outcomes of supplemental immunisation activities: 2017/2018 Nigeria measles vaccination campaign.
    Vaccine. 2021 Jan 15. pii: S0264-410X(20)31659.
    >> Share

  637. ZHAO X, Zeng X, Dai Q, Hou Y, et al
    Immunogenicity and protection efficacy of a Salmonella enterica serovar Typhimurium fnr, arcA and fliC mutant.
    Vaccine. 2021;39:588-595.
    >> Share

  638. VAN DEN BOOGAARD J, de Gier B, de Oliveira Bressane Lima P, Desai S, et al
    Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis.
    Vaccine. 2021 Jan 13. pii: S0264-410X(20)31691.
    >> Share

  639. WHITWORTH HS, Schiller J, Markowitz LE, Jit M, et al
    Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule.
    Vaccine. 2021 Jan 13. pii: S0264-410X(20)31598.
    >> Share

  640. OTERI J, Bawa S, Christopher E, Nsubuga P, et al
    Potential for improving routine immunisation waste management using measles vaccination campaign 2017 in Kebbi State, Nigeria.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31654.
    >> Share

  641. ATSMON J, Machluf N, Yagon-Gur V, Sabbah C, et al
    Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31630.
    >> Share

  642. YANG R, Liu Q, Pang W, Gao F, et al
    Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31674.
    >> Share

  643. ARCON N, Picchio MS, Fenoy IM, Moretta RE, et al
    Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31669.
    >> Share

  644. GUALANO MR, Corradi A, Voglino G, Catozzi D, et al
    Healthcare Workers' (HCWs) attitudes towards mandatory influenza vaccination: A systematic review and meta-analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31655.
    >> Share

  645. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    >> Share

  646. FENTON ATHR, Orefice C, Eun TJ, Biancarelli D, et al
    Effect of provider recommendation style on the length of adolescent vaccine discussions.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31441.
    >> Share

  647. KORNUTA CA, Langellotti CA, Bidart JE, Soria I, et al
    A plasmid encoding the extracellular domain of CD40 ligand and Montanide GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31553.
    >> Share

  648. SANTANA CP, Luhm KR, Shimakura SE
    Impact of Tdap vaccine during pregnancy on the incidence of pertussis in children under one year in Brazil - A time series analysis.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31636.
    >> Share

  649. ACKERSON B, Qian L, Sy LS, Bruxvoort K, et al
    Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31673.
    >> Share

  650. BURGER AE, Reither EN, Mamelund SE, Lim S, et al
    Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31666.
    >> Share

  651. SINGH J, Malik D, Raina A
    Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00015.
    >> Share

  652. RUIZ JB, Bell RA
    Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00014.
    >> Share

  653. WIEMKEN TL, Rutschman AS
    Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00018.
    >> Share

  654. BEIGI RH, Krubiner C, Jamieson DJ, Lyerly AD, et al
    The need for inclusion of pregnant women in COVID-19 vaccine trials.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31671.
    >> Share

  655. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    >> Share

  656. ABDI I, Gidding H, Leong RN, Moore HC, et al
    Vaccine coverage in children born to migrant mothers in Australia: A population-based cohort study.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31638.
    >> Share

  657. DESMET S, Wouters I, Heirstraeten LV, Beutels P, et al
    In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease.
    Vaccine. 2021;39:372-379.
    >> Share

  658. MAITI S, Howlader DR, Halder P, Bhaumik U, et al
    Bivalent non-typhoidal Salmonella outer membrane vesicles immunized mice sera confer passive protection against gastroenteritis in a suckling mice model.
    Vaccine. 2021;39:380-393.
    >> Share

  659. WILLIAMS J, Degeling C, McVernon J, Dawson A, et al
    How should we conduct pandemic vaccination?
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31639.
    >> Share

  660. SHARMA H, Anil K, Parekh S, Pujari P, et al
    A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31656.
    >> Share

  661. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    >> Share

  662. KELSO JM
    Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31696.
    >> Share

  663. SU JR, McNeil MM, Welsh KJ, Marquez PL, et al
    Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31614.
    >> Share

  664. NISAR MI, Ahmed S, Jehan F, Shahid S, et al
    Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31662.
    >> Share

  665. SCHEPPLER L, De Clercq N, McGoldrick M, Dias J, et al
    Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31569.
    >> Share

  666. KOHLI M, Maschio M, Becker D, Weinstein MC, et al
    The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31690.
    >> Share

  667. MIDDELDORP M, van Lier A, van der Maas N, Veldhuijzen I, et al
    Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31692.
    >> Share

  668. WONG MCS, Wong ELY, Huang J, Cheung AWL, et al
    Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31695.
    >> Share

  669. GODINOT LD, Sicsic J, Lachatre M, Bouvet E, et al
    Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Vaccine. 2021 Jan 5. pii: S0264-410X(20)31637.
    >> Share

  670. SCHLEY K, Malerczyk C, Beier D, Schiffner-Rohe J, et al
    Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany.
    Vaccine. 2021 Jan 4. pii: S0264-410X(20)31615.
    >> Share

  671. FIELDING J, Sullivan SG, Beard F, Macartney K, et al
    Constructing an ethical framework for priority allocation of pandemic vaccines.
    Vaccine. 2021 Jan 3. pii: S0264-410X(20)31633.
    >> Share

  672. RUSSELL LB, Kim SY, Toscano C, Cosgriff B, et al
    Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil.
    Vaccine. 2021;39:158-166.
    >> Share

  673. BAGATTINI AM, Policena G, Minamisava R, Andrade ALS, et al
    The data used to build the models: Pertussis morbidity and mortality burden considering various Brazilian data sources.
    Vaccine. 2021;39:137-146.
    >> Share

  674. RUSSELL LB, Sobanjo-Ter Meulen A, Toscano CM
    Evaluating the cost-effectiveness of maternal pertussis immunization in low- and middle-income countries: A review of lessons learnt.
    Vaccine. 2021;39:121-124.
    >> Share

  675. MITCHELL T, Dalal W, Klosovsky A, Yen C, et al
    An immunization program for US-bound refugees: Development, challenges, and opportunities 2012-present.
    Vaccine. 2021;39:68-77.
    >> Share

    December 2020
  676. JIANG X, Shang X, Lin J, Zhao Y, et al
    Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31608.
    >> Share

  677. GROVES PJ, Williamson SL, Ahaduzzaman M, Diamond M, et al
    Can a combination of vaccination, probiotic and organic acid treatment in layer hens protect against early life exposure to Salmonella Typhimurium and challenge at sexual maturity?
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31612.
    >> Share

  678. DAMJANOVSKA S, Smith C, Sayin I, Burant CJ, et al
    Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31631.
    >> Share

  679. SRINIVASA REDDY Y, Narendra Babu K, Uday Kumar P, Harishankar N, et al
    Nonclinical safety evaluation of oral recombinant anti-human papilloma virus vaccine (RHPV 16 & 18): Regulatory toxicology studies in mice, rats and rabbits - An innovative approach.
    Vaccine. 2020 Dec 30. pii: S0264-410X(20)31463.
    >> Share

  680. PRETO C, Maron de Mello A, Cesario Pereira Maluf EM, Teixeira Krainski E, et al
    Vaccination coverage and adherence to a dengue vaccination program in the state of Parana, Brazil.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31597.
    >> Share

  681. GUPTA S, Tiku VR, Gauhar M, Khatoon K, et al
    Genetic diversity of G9 rotavirus strains circulating among diarrheic children in North India: A comparison with 116E rotavirus vaccine strain.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31604.
    >> Share

  682. TOMLJENOVIC M, Petrovic G, Antoljak N, Hansen L, et al
    Vaccination attitudes, beliefs and behaviours among primary health care workers in northern Croatia.
    Vaccine. 2020 Dec 29. pii: S0264-410X(20)31502.
    >> Share

  683. ZHONG Y, Clapham HE, Aishworiya R, Chua YX, et al
    Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Vaccine. 2020 Dec 26. pii: S0264-410X(20)31634.
    >> Share

  684. PITTET LF, Tebruegge M, Dutta B, Donath S, et al
    Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guerin (BCG) vaccine.
    Vaccine. 2020 Dec 25. pii: S0264-410X(20)31498.
    >> Share

  685. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    >> Share

  686. MORO PL, Marquez P
    Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31613.
    >> Share

  687. ULANOVA M, Huska B, Desbiens A, Gaultier GN, et al
    Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31602.
    >> Share

  688. THANGARAJAH D, Malo JA, Field E, Andrews R, et al
    Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31579.
    >> Share

  689. KOSKAN A, Klasko-Foster L, Stecher C, Rodriguez S, et al
    Human papillomavirus vaccine guideline adherence among Arizona's Medicaid beneficiaries.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31609.
    >> Share

  690. CUI YA, Folaranmi T, Buchwald UK
    The Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial: Further reflections on the design and results.
    Vaccine. 2020 Dec 22. pii: S0264-410X(20)31600.
    >> Share

  691. APARECIDO NUNES A, De Jesus Lopes De Abreu A, Cintra O, A C T Cintra M, et al
    Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Vaccine. 2020 Dec 22. pii: S0264-410X(20)31542.
    >> Share

  692. GINI R, Dodd CN, Bollaerts K, Bartolini C, et al
    Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.
    Vaccine. 2020;38 Suppl 2:B56-B64.
    >> Share

  693. ITTEFAQ M, Baines A, Abwao M, Shah SFA, et al
    "Does Pakistan still have polio cases?": Exploring discussions on polio and polio vaccine in online news comments in Pakistan.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31607.
    >> Share

  694. MCFADDEN K, Seale H
    A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31610.
    >> Share

  695. RAMAKRISHNAN A, Joseph SS, Reynolds ND, Poncet D, et al
    Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.
    Vaccine. 2020 Dec 20. pii: S0264-410X(20)31601.
    >> Share

  696. MARCHAL C, Belhassen M, Guiso N, Jacoud F, et al
    Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data.
    Vaccine. 2020 Dec 20. pii: S0264-410X(20)31588.
    >> Share

  697. DOUGLASS N, van Diepen MT, Chapman R, Galant S, et al
    Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31591.
    >> Share

  698. FAN S, Liao Y, Jiang G, Wang L, et al
    Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31552.
    >> Share

  699. GRETER H, Ivol S, Oriol Mathieu V, Erismann S, et al
    Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31566.
    >> Share

  700. BETLACH AM, Fano E, VanderWaal K, Pieters M, et al
    Effect of multiple vaccinations on transmission and degree of Mycoplasma hyopneumoniae infection in gilts.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31443.
    >> Share

  701. KIM K, Hahn TW
    Evaluation of novel recombinant porcine circovirus type 2d (PCV2d) vaccine in pigs naturally infected with PCV2d.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31580.
    >> Share

  702. SPARROW E, Wood JG, Chadwick C, Newall AT, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2019.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31585.
    >> Share

  703. FULVINI AA, Tuteja A, Le J, Pokorny BA, et al
    HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31563.
    >> Share

  704. BORRIELLO A, Master D, Pellegrini A, Rose JM, et al
    Preferences for a COVID-19 vaccine in Australia.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31599.
    >> Share

  705. BOKEMPER SE, Huber GA, Gerber AS, James EK, et al
    Timing of COVID-19 vaccine approval and endorsement by public figures.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31616.
    >> Share

  706. MONTGOMERY VA, Lindsey CY, Smith LA, Webb RP, et al
    Development of an o-pthalaldehyde (OPA) assay to measure protein content in Ricin Vaccine E. coli (RVEc).
    Vaccine. 2020 Dec 15. pii: S0264-410X(20)31573.
    >> Share

  707. SANFTENBERG L, Kuehne F, Anraad C, Jung-Sievers C, et al
    Assessing the impact of shared decision making processes on influenza vaccination rates in adult patients in outpatient care: A systematic review and meta-analysis.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31581.
    >> Share

  708. BROOCKMAN D, Kalla J, Guerrero A, Budolfson M, et al
    Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31555.
    >> Share

  709. FLORES-VALDEZ MA, Segura-Cerda CA
    Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development?
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31556.
    >> Share

  710. STEVENS VW, Russo EM, Young-Xu Y, Leecaster M, et al
    Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trials.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31583.
    >> Share

  711. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    >> Share

  712. CASTANO-ZUBIETA MR, Rossetti CA, Garcia-Gonzalez DG, Maurizio E, et al
    Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDeltavjbR strain in goats.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31473.
    >> Share

  713. BOUCHEZ M, Ward JK, Bocquier A, Benamouzig D, et al
    Physicians' decision processes about the HPV vaccine: A qualitative study.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31586.
    >> Share

  714. SARINHO E, Goudouris E, Sole D
    BCG vaccine: Worrying proposal for COVID-19.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31593.
    >> Share

  715. DEGELING C, Williams J, Carter SM, Moss R, et al
    Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Vaccine. 2020 Dec 11. pii: S0264-410X(20)31577.
    >> Share

  716. ZACHARIA A, Harberts E, Valencia SM, Myers B, et al
    Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31541.
    >> Share

  717. DE OLIVEIRA EMERICK S, Vieira de Carvalho T, Meirelles Miranda B, Carneiro da Silva A, et al
    Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31539.
    >> Share

  718. LIU C, Huang P, Zhao D, Xia M, et al
    Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.
    Vaccine. 2020 Dec 10. pii: S0264-410X(20)31568.
    >> Share

  719. HOLM MR, Poland GA
    Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31584.
    >> Share

  720. CARIAS C, Pawaskar M, Nyaku M, Conway JH, et al
    Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US).
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31557.
    >> Share

  721. DULIN N, Spanier A, Merino K, Hutter JN, et al
    Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31495.
    >> Share

  722. GHASWALLA PK, Bengtson LGS, Marshall GS, Buikema AR, et al
    Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31550.
    >> Share

  723. RASTEGAR M, Tavana M, Meraj A, Mina H, et al
    An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31589.
    >> Share

  724. WILLIAMS JTB, Robinson K, Abbott E, Rojop N, et al
    Adapting and piloting a vaccine hesitancy questionnaire in rural Guatemala.
    Vaccine. 2020 Dec 8. pii: S0264-410X(20)31551.
    >> Share

  725. LUISI MLR
    From bad to worse II: Risk amplification of the HPV vaccine on Facebook.
    Vaccine. 2020 Dec 7. pii: S0264-410X(20)31540.
    >> Share

  726. GHIGA I, Richardson S, Alvarez AMR, Kato M, et al
    PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31500.
    >> Share

  727. DHAKAL S, Deshpande S, McMahon M, Strohmeier S, et al
    Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31510.
    >> Share

  728. LENG A, Maitland E, Wang S, Nicholas S, et al
    Individual preferences for COVID-19 vaccination in China.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31576.
    >> Share

  729. LLAU AF, Williams ML, Tejada CE
    National vaccine coverage trends and funding in Latin America and the Caribbean.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31534.
    >> Share

  730. DOLL MK, Weitzen SD, Morrison KT
    Trends in the uptake of pediatric measles-containing vaccine in the United States: A Disneyland effect?
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31501.
    >> Share

  731. WENZEL NS, Atkins KE, van Leeuwen E, Halloran ME, et al
    Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31282.
    >> Share

  732. MAYKIN MM, Heuser C, Feltovich H
    Pregnant people deserve the protection offered by SARS-CoV-2 vaccines.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31572.
    >> Share

  733. DIMOPOULOU D, Koutsaki M, Giorgi M, Spanou M, et al
    Effects of measles-containing vaccination in children with severe underlying neurologic disease.
    Vaccine. 2020 Dec 3. pii: S0264-410X(20)31536.
    >> Share

  734. LEADER AE, Burke-Garcia A, Massey PM, Roark JB, et al
    Understanding the messages and motivation of vaccine hesitant or refusing social media influencers.
    Vaccine. 2020 Dec 3. pii: S0264-410X(20)31533.
    >> Share

  735. MOHAMMED H, Roberts CT, Grzeskowiak LE, Giles LC, et al
    Safety of maternal pertussis vaccination on pregnancy and birth outcomes: A prospective cohort study.
    Vaccine. 2020 Dec 3. pii: S0264-410X(20)31505.
    >> Share

  736. OCRAN-APPIAH J, Boutry C, Herve C, Soni J, et al
    Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
    Vaccine. 2020 Dec 1. pii: S0264-410X(20)31323.
    >> Share

    November 2020
  737. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    >> Share

  738. FOCOSI D, Maggi F, Pistello M
    Corrigendum to "Getting the most from the Ebola vaccine success" [Vaccine 33 (2015) 7141].
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31537.
    >> Share

  739. HABER P, Tate J, Marquez PL, Moro PL, et al
    Safety profile of rotavirus vaccines among individuals aged>/=8months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019.
    Vaccine. 2020 Nov 29. pii: S0264-410X(20)31466.
    >> Share

  740. MAJED L, Bresse X, El Mouaddin N, Schmidt A, et al
    Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
    Vaccine. 2020 Nov 28. pii: S0264-410X(20)31420.
    >> Share

  741. GATES A, Gates M, Rahman S, Guitard S, et al
    A systematic review of factors that influence the acceptability of vaccines among Canadians.
    Vaccine. 2020 Nov 27. pii: S0264-410X(20)31332.
    >> Share

  742. DE CASTRO JC, de Almeida LV, Cardoso MS, Oliveira FMS, et al
    Vaccination with chimeric protein induces protection in murine model against ascariasis.
    Vaccine. 2020 Nov 26. pii: S0264-410X(20)31499.
    >> Share

  743. HAVERI A, Ikonen N, Savolainen-Kopra C, Julkunen I, et al
    Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31494.
    >> Share

  744. VANDER STICHELE RH, Hay C, Fladvad M, Sturkenboom MCJM, et al
    How to ensure we can track and trace global use of COVID-19 vaccines?
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31508.
    >> Share

  745. KITANO T, Aoki H
    A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31506.
    >> Share

  746. URA T, Yamashita A, Mizuki N, Okuda K, et al
    New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31507.
    >> Share

  747. KITTIKRAISAK W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, et al
    Comparison of influenza antibody titers among women who were vaccinated in the 2(nd) and the 3(rd) trimesters of pregnancy.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31472.
    >> Share

  748. DRORI Y, Pando R, Sefty H, Rosenberg A, et al
    Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31394.
    >> Share

  749. PECKEU L, van der Ende A, de Melker HE, Sanders EAM, et al
    Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31456.
    >> Share

  750. HU S, Xu X, Zhang Y, Liu Y, et al
    A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31469.
    >> Share

  751. HUANG Z, He J, Su J, Ou Z, et al
    Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Vaccine. 2020 Nov 22. pii: S0264-410X(20)31434.
    >> Share

  752. CLOSSON K, Karim ME, Sadarangani M, Naus M, et al
    Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
    Vaccine. 2020 Nov 22. pii: S0264-410X(20)31327.
    >> Share

  753. JULIAO P, Abadia I, Welby S, Wery S, et al
    Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama.
    Vaccine. 2020 Nov 22. pii: S0264-410X(20)31470.
    >> Share

  754. LINDSEY NP, Perry L, Fischer M, Woolpert T, et al
    Duration of seropositivity following yellow fever vaccination in U.S. military service members.
    Vaccine. 2020 Nov 22. pii: S0264-410X(20)31462.
    >> Share

  755. FIX A, Kirkwood CD, Steele D, Flores J, et al
    Next-generation rotavirus vaccine developers meeting: Summary of a meeting sponsored by PATH and the bill & melinda gates foundation (19-20 June 2019, Geneva).
    Vaccine. 2020 Nov 21. pii: S0264-410X(20)31474.
    >> Share

  756. OHFUJI S, Okada K, Mouri Y, Mihara Y, et al
    Effectiveness of four doses of pertussis vaccine during infancy diminished in elementary school age: A test-negative case-control study in Japan.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31475.
    >> Share

  757. ALLEN JC, Toapanta FR, Chen W, Tennant SM, et al
    Understanding immunosenescence and its impact on vaccination of older adults.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31426.
    >> Share

  758. GANGULY M, Yeolekar L, Tyagi P, Sagar U, et al
    Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31424.
    >> Share

  759. SUNDARAM ME, Wolfson J, Osterholm M, Sow S, et al
    Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt.
    Vaccine. 2020 Nov 19. pii: S0264-410X(20)31438.
    >> Share

  760. HOA-TRAN TN, Dao ATH, Nguyen AT, Kataoka C, et al
    Coxsackieviruses A6 and A16 associated with hand, foot, and mouth disease in Vietnam, 2008-2017: Essential information for rational vaccine design.
    Vaccine. 2020 Nov 19. pii: S0264-410X(20)31471.
    >> Share

  761. ZHU S, Chang J, Hayat K, Li P, et al
    Parental preferences for HPV vaccination in junior middle school girls in China: A discrete choice experiment.
    Vaccine. 2020 Nov 19. pii: S0264-410X(20)31460.
    >> Share

  762. YEUNG KHT, Lin SL, Clark A, McGhee SM, et al
    Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
    Vaccine. 2020 Nov 18. pii: S0264-410X(20)31361.
    >> Share

  763. THANH THI LE X, Ishizumi A, Thi Thu Nguyen H, Thi Duong H, et al
    Social and behavioral determinants of attitudes towards and practices of hepatitis B vaccine birth dose in Vietnam.
    Vaccine. 2020 Nov 18. pii: S0264-410X(20)31435.
    >> Share

  764. KHERA A, Singh R, Shakila H, Rao V, et al
    Corrigendum to 'Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis' [Vaccine 23 (2005) 5655-5665].
    Vaccine. 2020;38:7874-7875.
    >> Share

  765. GRAVAGNA K, Becker A, Valeris-Chacin R, Mohammed I, et al
    Global assessment of national mandatory vaccination policies and consequences of non-compliance.
    Vaccine. 2020;38:7865-7873.
    >> Share

  766. XU X, Wang C, Huang Y, Zhang S, et al
    Evaluation of the vaccine efficacy of three digestive protease antigens from Dermanyssus gallinae using an in vivo rearing system.
    Vaccine. 2020;38:7842-7849.
    >> Share

  767. BAROUTSOU V, Zens KD, Sinniger P, Fehr J, et al
    Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018.
    Vaccine. 2020;38:7825-7833.
    >> Share

  768. PHUGARE S, Kale S, Sharma P, Kumar Goel S, et al
    Quantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA.
    Vaccine. 2020;38:7815-7824.
    >> Share

  769. TUCKERMAN JL, Kaufman J, Danchin M, Marshall HS, et al
    Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions.
    Vaccine. 2020;38:7806-7814.
    >> Share

  770. GUESS AM, Nyhan B, O'Keeffe Z, Reifler J, et al
    The sources and correlates of exposure to vaccine-related (mis)information online.
    Vaccine. 2020;38:7799-7805.
    >> Share

  771. PHILLIPS MT, Warren JL, Givon-Lavi N, Tothpal A, et al
    Evaluating post-vaccine expansion patterns of pneumococcal serotypes.
    Vaccine. 2020;38:7756-7763.
    >> Share

  772. HEO JY, Seo YB, Jeong HW, Choi MJ, et al
    Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines.
    Vaccine. 2020;38:7747-7755.
    >> Share

  773. MOHAMED N, Simba D, Mphuru A, Lyimo D, et al
    Lessons learned in the implementation of supplementary immunization activity (SIA) field guidelines for injectable vaccines - Experiences from Tanzania.
    Vaccine. 2020;38:7741-7746.
    >> Share

  774. TOLL M, Li A
    Vaccine sentiments and under-vaccination: Attitudes and behaviour around Measles, Mumps, and Rubella vaccine (MMR) in an Australian cohort.
    Vaccine. 2020 Nov 17. pii: S0264-410X(20)31461.
    >> Share

  775. XIAOJIN S, Rodewald LE, Guomin Z, Hui Z, et al
    Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study.
    Vaccine. 2020 Nov 16. pii: S0264-410X(20)31457.
    >> Share

  776. MAGWIRA CA, Kgosana LP, Esona MD, Seheri ML, et al
    Low fecal rotavirus vaccine virus shedding is significantly associated with non-secretor histo-blood group antigen phenotype among infants in northern Pretoria, South Africa.
    Vaccine. 2020 Nov 16. pii: S0264-410X(20)31465.
    >> Share

  777. ROBERTS JR, Dawley E, Garbe C, Cooper T, et al
    A survey of office practice: Parents, front office staff, nurses and clinicians hold disparate views on adolescent vaccines.
    Vaccine. 2020 Nov 15. pii: S0264-410X(20)31440.
    >> Share

  778. SHEARER JD, Henning L, Sanford DC, Li N, et al
    Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
    Vaccine. 2020 Nov 13. pii: S0264-410X(20)31433.
    >> Share

  779. ZUO XX, Zhao YH, Zhou MX, Deng BH, et al
    Live vaccine preserved at room temperature: Preparation and characterization of a freeze-dried classical swine fever virus vaccine.
    Vaccine. 2020 Nov 13. pii: S0264-410X(20)31425.
    >> Share

  780. JARRETT S, Wilmansyah T, Bramanti Y, Alitamsar H, et al
    The role of manufacturers in the implementation of global traceability standards in the supply chain to combat vaccine counterfeiting and enhance safety monitoring.
    Vaccine. 2020 Nov 13. pii: S0264-410X(20)31437.
    >> Share

  781. VYSE A, Campling J, Czudek C, Ellsbury G, et al
    The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in
    Vaccine. 2020 Nov 12. pii: S0264-410X(20)31421.
    >> Share

  782. CROOKE SN, Riggenbach MM, Ovsyannikova IG, Warner ND, et al
    Durability of humoral immune responses to rubella following MMR vaccination.
    Vaccine. 2020 Nov 12. pii: S0264-410X(20)31396.
    >> Share

  783. WANG Q, Zhang W, Cai H, Cao Y, et al
    Understanding the perceptions of Chinese women of the commercially available domestic and imported HPV vaccine: A semantic network analysis.
    Vaccine. 2020 Nov 12. pii: S0264-410X(20)31442.
    >> Share

  784. MASHININI DP, Fogarty KJ, Potter RC, Berles JD, et al
    Geographic hot spot analysis of vaccine exemption clustering patterns in Michigan from 2008 to 2017.
    Vaccine. 2020 Nov 12. pii: S0264-410X(20)31422.
    >> Share

  785. KWON WJ, Choi JC, Hong S, Kim YC, et al
    Development of a high-dose vaccine formulation for prevention of megalocytivirus infection in rock bream (Oplegnathus fasciatus).
    Vaccine. 2020 Nov 11. pii: S0264-410X(20)31423.
    >> Share

  786. HALL LM, Ediriweera Y, Banks J, Nambiar A, et al
    Cooling to reduce the pain associated with vaccination: A systematic review.
    Vaccine. 2020 Nov 11. pii: S0264-410X(20)31429.
    >> Share

  787. GARCIA LY, Cerda AA
    Acceptance of a COVID-19 vaccine: A multifactorial consideration.
    Vaccine. 2020;38:7587.
    >> Share

  788. GRAFFIGNA G, Palamenghi L, Barello S, Stefania B, et al
    "Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.
    Vaccine. 2020;38:7585-7586.
    >> Share

  789. COUDEVILLE L, Gomez GB, Jollivet O, Harris RC, et al
    Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Vaccine. 2020;38:7588-7595.
    >> Share

  790. DOUBOVETZKY M, Ataman-Onal Y, Chousterman B, Feroldi E, et al
    Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
    Vaccine. 2020 Nov 10. pii: S0264-410X(20)31306.
    >> Share

  791. JUSTHY DP
    Vaccine as a Platform (VaaP): Why the future of disease eradication needs to be data driven.
    Vaccine. 2020 Nov 10. pii: S0264-410X(20)31403.
    >> Share

  792. NAVIN MC, Danchin M
    Vaccine mandates in the US and Australia: balancing benefits and burdens for children and physicians.
    Vaccine. 2020 Nov 9. pii: S0264-410X(20)31400.
    >> Share

  793. ZHANG W, Gao J, Chen L, Tian J, et al
    Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons.
    Vaccine. 2020 Nov 8. pii: S0264-410X(20)31389.
    >> Share

  794. FORTUNA L, Chaithongwongwatthana S, Soonthornworasiri N, Spiegel J, et al
    Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen(R)) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen(R)) vaccine for immunization of adolescents and a
    Vaccine. 2020 Nov 8. pii: S0264-410X(20)31390.
    >> Share

  795. MAUBRIGADES LR, Santos FDS, Goncalves VS, Rodrigues PRC, et al
    Association of Bacillus toyonensis spores with alum improves bovine herpesvirus 5 subunit vaccine immune response in mice.
    Vaccine. 2020 Nov 7. pii: S0264-410X(20)31386.
    >> Share

  796. MURALL CL, Reyne B, Selinger C, Bernat C, et al
    HPV cervical infections and serological status in vaccinated and unvaccinated women.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31398.
    >> Share

  797. CHIU SS, Chua H, Kwan MYW, Chan ELY, et al
    Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31401.
    >> Share

  798. GIRISH KUMAR CP, Giri S, Chawla-Sarkar M, Gopalkrishna V, et al
    Epidemiology of rotavirus diarrhea among children less than 5 years hospitalized with acute gastroenteritis prior to rotavirus vaccine introduction in India.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31404.
    >> Share

  799. CHEN RT, Kochhar S, Condit R
    The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG).
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31392.
    >> Share

  800. SARASTY O, Carpio CE, Hudson D, Guerrero-Ochoa PA, et al
    The demand for a COVID-19 vaccine in Ecuador.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31439.
    >> Share

  801. BULULA N, Mwiru DP, Swalehe O, Thomas Mori A, et al
    Vaccine storage and distribution between expanded program on immunization and medical store department in Tanzania: a cost-minimization analysis.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31419.
    >> Share

  802. SIKORA AE, Gomez C, Le Van A, Baarda BI, et al
    A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31397.
    >> Share

  803. HITCHINGS MDT, Cummings DAT, Grais RF, Isanaka S, et al
    A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31399.
    >> Share

  804. KESKE S, Mutters NT, Tsioutis C, Ergonul O, et al
    Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31427.
    >> Share

  805. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    >> Share

  806. SEITEL T, Cagol L, Prelog M, Frivolt K, et al
    Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31322.
    >> Share

  807. GRIFFITH BC, Ulrich AK, Becker AB, Nederhoff D, et al
    Does education about local vaccination rates and the importance of herd immunity change US parents' concern about measles?
    Vaccine. 2020 Nov 3. pii: S0264-410X(20)31258.
    >> Share

  808. LOWELL JA, Dikici E, Joshi PM, Landgraf R, et al
    Vaccination against cocaine using a modifiable dendrimer nanoparticle platform.
    Vaccine. 2020 Nov 3. pii: S0264-410X(20)31335.
    >> Share

  809. CROOKE SN, Ovsyannikova IG, Kennedy RB, Warner ND, et al
    Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.
    Vaccine. 2020 Nov 3. pii: S0264-410X(20)31391.
    >> Share

  810. CHEN WH, Tao X, Agrawal AS, Algaissi A, et al
    Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Vaccine. 2020;38:7533-7541.
    >> Share

  811. PEUBEZ I, Margot S, Buffin S, Pion C, et al
    A novel lamprey antibody sequence to multimerize and increase the immunogenicity of recombinant viral and bacterial vaccine antigens.
    Vaccine. 2020 Nov 2. pii: S0264-410X(20)31393.
    >> Share

    October 2020
  812. UDDEN F, Filipe M, Slotved HC, Yamba-Yamba L, et al
    Pneumococcal carriage among children aged 4 - 12 years in Angola 4 years after the introduction of a pneumococcal conjugate vaccine.
    Vaccine. 2020 Oct 31. pii: S0264-410X(20)31369.
    >> Share

  813. MANGION M, Gelinas JF, Bakhshi Zadeh Gashti A, Azizi H, et al
    Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31367.
    >> Share

  814. SHARMA T, Joshi N, Kumar Mandyal A, Nordqvist SL, et al
    Development of Hillchol(R), a low-cost inactivated single strain Hikojima oral cholera vaccine.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31337.
    >> Share

  815. VESIKARI T, Ramsey K, Pitisuttithum P, Capeding R, et al
    Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31330.
    >> Share

  816. LOLI S, Carcamo CP
    Rotavirus vaccination and stunting: Secondary Data Analysis from the Peruvian Demographic and Health Survey.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31338.
    >> Share

  817. PALANIAPPAN PA, Mohamed Sukur S, Liow YL, Maniam S, et al
    Carriage of Haemophilus influenzae among children attending childcare centres in Kuala Lumpur, Malaysia in the post vaccination era: A cross-sectional study.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31237.
    >> Share

  818. SAITOH A, Saitoh A, Katsuta T, Mine M, et al
    Effect of a vaccine information statement (VIS) on immunization status and parental knowledge, attitudes, and beliefs regarding infant immunization in Japan.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31355.
    >> Share

  819. BONANNI P, Angelillo IF, Villani A, Biasci P, et al
    Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic: Appeal from the Board of the Vaccination Calendar for Life in Italy: Maintain and increase coverage also by r
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31318.
    >> Share